

CITATION REPORT

List of articles citing

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

DOI: 10.1093/annonc/mdw235

Annals of Oncology, 2016, 27, 1386-422.

Source: <https://exaly.com/paper-pdf/63483655/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2154	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. 2016 , 2016, 9850690		15
2153	How the lab is changing our view of colorectal cancer. 2016 , 102, 541-547		9
2152	Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers. 2016 , 17,		11
2151	Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. <i>Annals of Oncology</i> , 2016 , 27, 2203-2210	10.3	18
2150	The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer. 2016 , 76, 6443-6444		6
2149	High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection. 2016 , 33, 121		18
2148	Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer. 2016 , 76, 1393-402		30
2147	Targeted Therapy of Colorectal Cancer. 2016 , 39, 796-802		28
2146	Palliative Therapie des kolorektalen Karzinoms. 2016 , 11, 464-478		
2145	Interdisziplinäre Therapie kolorektaler Lebermetastasen. 2016 , 11, 479-488		2
2144	Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?. 2016 , 69, 178-179		2
2143	Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer. 2016 , 12, 303-313		
2142	Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. 2017 , 20, 574-584		6
2141	Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded). 2017 , 104, 402-406		8
2140	FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?. 2017 , 73, 71-73		
2139	Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. 2017 , 13, 415-423		17
2138	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. 2017 , 16, e153-e163		70

2137	Advanced colorectal cancer treatment options beyond standard systemic therapy. 2017 , 18, 157-159	5
2136	Determinants of metastatic competency in colorectal cancer. 2017 , 11, 97-119	101
2135	First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm. 2017 , 14, 113	16
2134	The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. 2017 , 18, 197-200	7
2133	[Optimized detection and characterization of liver metastases : The role of current MRI contrast agents]. 2017 , 57, 373-381	1
2132	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. 2017 , 174, 145-172	19
2131	Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice. 2017 , 13, 81-90	
2130	Geriatric factors and outcomes in metastatic colorectal cancer. 2017 , 74, 96-97	0
2129	BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. 2017 , 18, 9	41
2128	[Colorectal cancer in the elderly. Surgical treatment, chemotherapy, and contribution from geriatrics]. 2017 , 52, 261-270	3
2127	The role of image-guided therapy in the management of colorectal cancer metastatic disease. 2017 , 75, 231-242	28
2126	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. <i>Annals of Oncology</i> , 2017 , 28, 958-968	10.3 53
2125	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. <i>Annals of Oncology</i> , 2017 , 28, 1713-1729	10.3 454
2124	Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. 2017 , 78, 7-15	30
2123	Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2017 , 28, 1325-1332	10.3 183
2122	A Complete Response Case in a Patient with Multiple Lung Metastases of Rectal Cancer Treated with Bevacizumab plus XELIRI Therapy. 2017 , 10, 81-85	1
2121	Future perspectives of circulating tumor DNA in colorectal cancer. 2017 , 39, 1010428317705749	10
2120	Lethal hepatotoxicity following 5-fluorouracil/cisplatin chemotherapy: a relevant case report. 2017 , 14, 197-201	2

2119	Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies. 2017 , 59, 54-60	59
2118	Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. 2017 , 1-16	
2117	Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. 2017 , 79, 50-60	75
2116	Comprehensive Review on Colorectal Cancer and Transplant. 2017 , 17, 2761-2774	9
2115	First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). 2017 , 81, 191-202	52
2114	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. 2017 , 117, 315-321	15
2113	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. 2017 , 81, 26-35	6
2112	Evolution and revolution of laparoscopic liver resection in Japan. 2017 , 1, 33-43	30
2111	Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age. 2017 , 6, 1255-1263	18
2110	In vitro additive antitumor effects of dimethoxycurcumin and 5-fluorouracil in colon cancer cells. 2017 , 6, 1698-1706	20
2109	Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm. 2017 , 471, 235-242	6
2108	Genetic and epigenetic markers in colorectal cancer screening: recent advances. 2017 , 17, 665-685	15
2107	Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy. 2017 , 115, 59-66	12
2106	Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. 2017 , 113, 242-248	52
2105	Clinical Impact of Preoperative Chemotherapy on Microscopic Cancer Spread Surrounding Colorectal Liver Metastases. 2017 , 24, 2326-2333	9
2104	Immunotherapy for colorectal cancer: where are we heading?. 2017 , 17, 709-721	71
2103	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. 2018 , 249, 145-159	1
2102	DPD testing must remain a recommended option, but not a recommended routine test. <i>Annals of Oncology</i> , 2017 , 28, 1399	103 4

2101	Immunotherapy for gastric cancers: emerging role and future perspectives. 2017 , 10, 609-619	26
2100	Trifluridine/tipiracil in metastatic colorectal cancer: a guide to its use. 2017 , 33, 110-118	7
2099	Sulfatase-2 promotes the growth and metastasis of colorectal cancer by activating Akt and Erk1/2 pathways. 2017 , 89, 1370-1377	15
2098	From tumour heterogeneity to advances in precision treatment of colorectal cancer. 2017 , 14, 235-246	307
2097	Current and future biomarkers in the treatment of colorectal cancer. 2017 , 72, 103-115	21
2096	ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. 2017 , 110, 81-93	32
2095	High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. 2017 , 19, 718-726	12
2094	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. 2017 , 73, 74-84	32
2093	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. 2017 , 86, 305-317	17
2092	CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer. 2017 , 12, 787-794	4
2091	Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point. 2017 , 39, 2135-2145	6
2090	Primary tumor resection in stage IV unresectable colorectal cancer: what has changed?. 2017 , 34, 188	9
2089	Gastrointestinal Cancers. 2017 , 589-625	1
2088	The current status of treatment for colorectal cancer in China: A systematic review. 2017 , 96, e8242	59
2087	Chronic Oxaliplatin-Based Chemotherapy in a Primary Ampullary Adenocarcinoma Patient without Significant Peripheral Neuropathy: Case Report and Literature Review. 2017 , 10, 577-581	2
2086	Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database. 2017 , 12, 805-814	13
2085	First-line treatment in metastatic colorectal cancer: Important or crucial?. 2017 , 84, 363-366	2
2084	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. <i>Annals of Oncology</i> , 2017 , 28, 3009-3014	10.3 48

2083	A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study. 2017 , 80, 1133-1139	4
2082	Intraluminal rectal cancer metastasis to the small bowel: An extremely rare case report. 2017 , 7, 553-556	5
2081	Percutaneous thermal ablation of lung tumors - Radiofrequency, microwave and cryotherapy: Where are we going?. 2017 , 98, 619-625	48
2080	Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. 2017 , 117, 1269-1277	34
2079	FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land. 2017 , 408, 71-72	1
2078	Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer. 2017 , 28, 1166-1173	3
2077	Transarterial (chemo)embolisation versus chemotherapy for colorectal cancer liver metastases. 2017 ,	0
2076	The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection. 2017 , 43, 2001-2011	14
2075	Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. 2017 , 13, 2065-2082	7
2074	Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases. 2017 , 24, 3857-3864	10
2073	Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer. 2017 , 51, 515-524	25
2072	Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. 2017 , 118, 54-62	37
2071	Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes. 2017 , 58, 104S-111S	24
2070	The safety and effectiveness of robot-assisted versus laparoscopic TME in patients with rectal cancer: A meta-analysis and systematic review. 2017 , 96, e7585	37
2069	Cáncer colorrectal. 2017 , 12, 1911-1918	
2068	TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. 2017 , 18, 1172-1181	72
2067	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. 2017 , 17, 1297-1308	17
2066	Using pharmacogenetics to prevent severe adverse reactions to capecitabine. 2017 , 18, 1199-1213	2

2065	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer-A definite conclusion?. 2017 , 44, 129-131	2
2064	Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. 2017 , 44, 159-160	4
2063	Recent developments in the treatment of metastatic colorectal cancer. 2017 , 9, 551-564	68
2062	Radioembolization. 2017 , 143-155	
2061	Radioembolisation mit Yttrium-90-Mikrosphären. 2017 , 23, 609-618	
2060	The Allosteric Hemoglobin Effector ITPP Inhibits Metastatic Colon Cancer in Mice. 2017 , 266, 746-753	6
2059	Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. 2017 , 84, 69-80	136
2058	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. 2017 , 2, e000177	19
2057	Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. 2017 , 12, 599-610	68
2056	DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. <i>Annals of Oncology</i> , 2017 , 28, 2915-2922	10.3 38
2055	SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer. 2017 , 7, 17597	15
2054	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. 2017 , 2, e000241	6
2053	Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. 2017 , 117, 1768-1776	8
2052	Prognostic value of CD133 CD54 CD44 circulating tumor cells in colorectal cancer with liver metastasis. 2017 , 6, 2850-2857	21
2051	Comparison of Ras/Raf/MAPK signaling pathway in primary tumour and lymph node metastases - A report on an experimental study of two colorectal cancer cell lines (SW480 and SW620) and tissue samples. 2017 , 2, 215	
2050	MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy. 2017 , 18, 1027-1038	5
2049	The management of colorectal liver metastases. 2017 , 72, 617-625	17
2048	Treatment of Refractory Colorectal Cancer: Regorafenib vs. TAS-102. 2017 , 13, 325-333	

2047	Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. 2017 , 10, 693-698		6
2046	FIRE-4.5-Studie. 2017 , 32, 54-56		3
2045	Oligometastasierung in Zeiten bildgeffilterter Ablationsverfahren. 2017 , 32, 242-245		
2044	Personalizing Maintenance Therapy in Metastatic Colorectal Cancer. 2017 , 13, 205-211		1
2043	Peribiliary liver metastases MR findings. 2017 , 34, 124		9
2042	Surgical Outcome and Prognostic Stratification for Pulmonary Metastasis From Colorectal Cancer. 2017 , 104, 979-987		45
2041	Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. 2017 , 22, 864-872		45
2040	Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. <i>Annals of Oncology</i> , 2017 , 28, 2149-2159	10.3	73
2039	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). 2017 , 23, 5416-5425		129
2038	Positron Emission Tomography-Computed Tomography for Patients with Recurrent Colorectal Liver Metastases: Impact on Restaging and Treatment Planning. 2017 , 24, 1029-1036		14
2037	Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?. <i>Annals of Oncology</i> , 2017 , 28, 183	10.3	12
2036	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. 2017 , 16, e191-e198		9
2035	Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017 , 28, 184	10.3	14
2034	The IR Evolution in Oncology: Tools, Treatments, and Guidelines. 2017 , 40, 3-8		4
2033	Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. 2017 , 79, 9-16		9
2032	Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. 2017 , 2, e000229		10
2031	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017 , 28, iv22-iv40	10.3	627
2030	Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test. 2017 , 14, 6045-6052		5

2029	Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. <i>Annals of Oncology</i> , 2017 , 28, 2943-2949	10.3	51
2028	CT-Guided Tumor Ablation. 2017 , 945-956		
2027	Correction: Radioembolisation mit Yttrium-90-Mikrosphären. 2017 , 23, 951-960		
2026	Unique case of herniated small bowel infarction within a colonic stomal prolapse. 2017 , 2017,		1
2025	Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. 2017 , 18,		65
2024	Clinical Application of CT-Guided Percutaneous Microwave Ablation for the Treatment of Lung Metastasis from Colorectal Cancer. 2017 , 2017, 9621585		2
2023	Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes-An ESDO Report. 2017 , 9,		3
2022	Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. 2017 , 2017, 2683478		2
2021	Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. 2017 , 17, 548		6
2020	Next-generation sequencing: recent applications to the analysis of colorectal cancer. 2017 , 15, 246		40
2019	Zielgerichtete Next-Generation-Sequencing-basierte Panelsequenzierung in Kombination mit immunhistochemischen Standardanalysen. 2017 , 32, 384-392		
2018	Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. 2017 , 36, 81		8
2017	Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. 2017 , 90, 377-384		3
2016	Long-term survival after a favorable response to anti-EGFR antibody plus chemotherapy to treat bone marrow metastasis: a case report of -wildtype rectal cancer. 2017 , 10, 1143-1147		3
2015	Patient considerations in metastatic colorectal cancer - role of panitumumab. 2017 , 10, 2033-2044		7
2014	Making Meaningful Clinical Use of Biomarkers. 2017 , 12, 1177271917715236		76
2013	Not All BRAF-Mutant Metastatic Colorectal Cancers Are Identical: Distinct Clinical Consequences of BRAF Mutations. 2017 , 35, 2598-2599		2
2012	Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. 2017 , 37, 246-256		13

2011	Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. 2017 , 8, 93567-93579	19
2010	Primary and acquired resistance to biologic therapies in gastrointestinal cancers. 2017 , 8, 499-512	9
2009	Multidisciplinary approach of colorectal cancer liver metastases. 2017 , 8, 190-202	32
2008	[Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPgX networks]. 2018 , 105, 397-407	49
2007	CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 1227-1234	10.3 49
2006	Results and challenges of immune checkpoint inhibitors in colorectal cancer. 2018 , 18, 561-573	38
2005	A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. 2018 , 17, 147-155	31
2004	Current Trends on the Treatment Sequence for Colorectal Cancer with Liver Metastases. 2018 , 14, 64-68	
2003	Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?. 2018 , 25, 1676-1685	22
2002	Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: an original Pt(IV) pro-drug based on Cisplatin and Tranilast. 2018 , 54, 8324-8327	7
2001	MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. 2018 , 144, 1197-1204	11
2000	DNA mismatch repair in cancer. 2018 , 189, 45-62	171
1999	What Chemotherapy to Recommend in Metastatic Patients?. 2018 , 339-348	
1998	Recent advances in treatment for colorectal liver metastasis. 2018 , 2, 167-175	16
1997	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. 2018 , 1-27	1
1996	Clinical importance of DNA repair in sporadic colorectal cancer. 2018 , 126, 168-185	9
1995	Role of circulating tumor DNA in the management of patients with colorectal cancer. 2018 , 42, 396-402	11
1994	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 1108-1119	10.3 101

1993	Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San Jos, Costa Rica, August 2016. 2018 , 3, e000315		7
1992	Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?. 2018 , 57, 750-758		5
1991	Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. <i>Annals of Oncology</i> , 2018 , 29, 835-856	10.3	38
1990	CD133 expression predicts post-operative recurrence in patients with colon cancer with peritoneal metastasis. 2018 , 52, 721-732		9
1989	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 2018 , 4, 529-536		51
1988	Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. 2018 , 28, 2969-2978		12
1987	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. 2018 , 3, e000299		24
1986	Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial. <i>Annals of Oncology</i> , 2018 , 29, 931-937	10.3	13
1985	Postoperative CEA is a better prognostic marker than CA19-9, hCG α or TATI after resection of colorectal liver metastases. 2018 , 40, 1010428317752944		11
1984	Comparison of Western and Asian Guidelines Concerning the Management of Colon Cancer. 2018 , 61, 250-259		23
1983	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. 2018 , 18, 251-266		29
1982	Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. 2018 , 28, 2727-2734		59
1981	RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGE0 RASANC prospective multicenter study. <i>Annals of Oncology</i> , 2018 , 29, 1211-1219	10.3	84
1980	Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. <i>Annals of Oncology</i> , 2018 , 29, 439-444	10.3	10
1979	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2018 , 29, 44-70	10.3	260
1978	Comparison of the guidelines for colorectal cancer in Japan, the USA and Europe. 2018 , 2, 6-12		31
1977	Trends in presentation, treatment and survival of 1777 patients with colorectal cancer over a decade: a Biobank study. 2018 , 57, 735-742		4
1976	Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group. 2018 , 17, 58-64		18

1975	Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. 2018 , 91, 153-163	62
1974	Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study. 2018 , 17, e233-e255	17
1973	Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas. 2018 , 109, 250-258	14
1972	Pharmacogenomics: time to rethink its role in precision medicine. <i>Annals of Oncology</i> , 2018 , 29, 293-295	10,3
1971	A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. 2018 , 18, 371	14
1970	Stereotactically navigated percutaneous microwave ablation (MWA) compared to conventional MWA: a matched pair analysis. 2018 , 13, 1991-1997	12
1969	Management and grading of EGFR inhibitor-induced cutaneous toxicity. 2018 , 14, 2531-2541	19
1968	RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. <i>Annals of Oncology</i> , 2018 , 29, 112-118	10,3 57
1967	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. 2018 , 14, 1629-1645	14
1966	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. 2018 , 69, 353-358	200
1965	Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. 2018 , 472, 959-968	10
1964	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. 2018 , 23, 1310-1318	32
1963	Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. 2018 , 98, 69-74	5
1962	Technical Validation of a Reverse-Transcription Quantitative Polymerase Chain Reaction In Vitro Diagnostic Test for the Determination of MiR-31-3p Expression Levels in Formalin-Fixed Paraffin-Embedded Metastatic Colorectal Cancer Tumor Specimens. 2018 , 13, 1177271918763357	12
1961	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. 2018 , 17, e457-e470	14
1960	Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?. <i>Annals of Oncology</i> , 2018 , 29, 1083-1084	10,3 8
1959	A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. 2018 , 52, 1391-1400	6
1958	Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first. 2018 , 20, 1274-1279	8

1957	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. 2018 , 17, 165-169	44
1956	Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?. 2018 , 19, 659-663	7
1955	Regorafenib in the treatment of metastatic colorectal cancer. 2018 , 14, 2239-2246	7
1954	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. 2018 , 19, 660-671	68
1953	Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer. 2018 , 19, 587-589	3
1952	Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with wild-type metastatic colorectal carcinoma. 2018 , 3, e000297	15
1951	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. 2018 , 118, 955-965	10
1950	Prognostic value of carcinoembryonic antigen level in patients with colorectal cancer liver metastasis treated with percutaneous microwave ablation under ultrasound guidance. 2018 , 97, e0044	6
1949	Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records. 2018 , 49, 245-251	7
1948	Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review. 2018 , 17, e1-e12	13
1947	Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. 2018 , 142, 1047-1055	8
1946	Liquid biopsy: another tool towards tailored therapy in colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 7-8	10.3 7
1945	Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. 2018 , 71, 336-343	17
1944	Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis. 2018 , 17, e91-e97	15
1943	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Kline Prognostic Category and BRAF Mutation Status. 2018 , 17, 50-57.e8	5
1942	Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review. 2018 , 9, 15-23	19
1941	Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. 2018 , 9, 32-39	25
1940	Impact of Metastasectomy in the Multimodality Approach for V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. 2018 , 23, 128-134	25

1939	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. 2018 , 24, 1062-1072	143
1938	5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases. 2018 , 42, 255-260	6
1937	Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. 2018 , 17, e189-e199	16
1936	Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. 2018 , 88, 77-86	38
1935	Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study. 2018 , 17, e99-e107	2
1934	Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmagafodipir (PledOx): a placebo-controlled randomised phase II study (PLIANT). 2018 , 57, 393-402	52
1933	Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS). 2018 , 9, 93-101	8
1932	The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. 2018 , 121, 1-10	35
1931	Early recurrence in patients undergoing curative resection of colorectal liver oligometastases: identification of its clinical characteristics, risk factors, and prognosis. 2018 , 144, 359-369	21
1930	Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review. 2018 , 62, 61-73	34
1929	Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. 2018 , 9, 18698-18711	83
1928	SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. 2018 , 9, 25355-25382	22
1927	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. 2018 , 36, 2052-2060	19
1926	Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. 2018 , 36, 3031-3039	89
1925	Circulating Cell-free Tumor Nucleic Acids in Gastric Cancer. 2018 , 18, 168	
1924	In search of evidence - PIPAC on the fast lane. 2018 , 3, 20180119	4
1923	Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. 2018 , 36, 350-358	99
1922	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. 2018 , 36, 773-779	938

1921	Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. 2018 , 2018,	31
1920	Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer. 2018 , 13, e0209838	5
1919	Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. 2018 , 9, E23-E27	6
1918	Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high-risk colon cancer patients - study protocol for the PIPAC-OPC3 Trial. A prospective, controlled phase 2 Study. 2018 , 3, 20180107	12
1917	Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: Surgeon's perspective. 2018 , 3, 20180102	9
1916	TumorEncode - Deep Convolutional Autoencoder for Computed Tomography Tumor Treatment Assessment. 2018 ,	
1915	EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment.. 2018 , 2, 1-6	5
1914	Recent advances in understanding colorectal cancer. 2018 , 7,	10
1913	Metachronous rectal metastasis from primary transverse colon cancer: a case report. 2018 , 4, 90	7
1912	Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin. 2018 , 8, 16579	5
1911	Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study. 2018 , 20, 1219-1226	15
1910	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial. 2018 , 8, 474	11
1909	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. 2018 , 119, 1464-1470	40
1908	The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases. 2018 , 19,	58
1907	Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer. 2018 , 18, 1124	8
1906	Mutation Status and Immunohistochemical Correlation of , and in 260 Chinese Colorectal and Gastric Cancers. 2018 , 8, 487	14
1905	The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. 2018 , 8, 1518-1528	51
1904	Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases. 2018 , 9, 587-591	2

1903	The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab. 2018 , 9, 30279-30288	3
1902	Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?. 2018 , 1110, 75-100	3
1901	Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy. 2018 , 2018, 9450754	21
1900	A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients. 2018 , 10, 6061-6070	5
1899	Complete Response of Pulmonary Metastases from Rectal Cancer to Tegafur-Uracil/Leucovorin plus Bevacizumab in an Elderly Patient: A Case Report. 2018 , 11, 461-466	
1898	Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?. 2018 , 19,	80
1897	Chemoprevention of Colorectal Cancer by Dietary Compounds. 2018 , 19,	39
1896	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. 2018 , 40, 1010428318811207	8
1895	Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis. 2018 , 19, 77	4
1894	Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. 2018 , 13, 234	40
1893	Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer. 2018 , 9, 4092-4098	1
1892	Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. 2018 , 18, 957	4
1891	The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. 2018 , 16, 273	41
1890	Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?. 2018 , 55, 330-379	55
1889	The Role of Liver-Directed Therapy in Metastatic Colorectal Cancer. 2018 , 14, 129-137	7
1888	Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer. 2018 , 487, 107-111	8
1887	Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer. 2018 , 16, 6589-6597	10
1886	Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer. 2018 , 82, 987-997	5

1885	Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?. 2018 , 38, 29	15
1884	Pharmacogenetic testing in oncology: a Brazilian perspective. 2018 , 73, e565s	4
1883	A comparison between 915 MHz and 2450 MHz microwave ablation systems for the treatment of small diameter lung metastases. 2018 , 24, 31-37	15
1882	An international survey-based study on colorectal cancer pathology reporting-guidelines versus local practice. 2018 , 473, 697-708	2
1881	"Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. 2018 , 8, 23	9
1880	Insurance status does not affect short-term outcomes after oncological colorectal surgery in Europe, but influences the use of minimally invasive techniques: a propensity score-matched analysis. 2018 , 403, 863-872	2
1879	Nomograms for estimating survival in patients with liver-only colorectal metastases: A retrospective study. 2018 , 60, 1-8	9
1878	Do we make progress in elderly patients with metastatic colorectal cancer?. 2018 , 57, 1422-1426	2
1877	Quality Care. 2018 , 49-69	
1876	Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer. 2018 , 11, 7295-7300	5
1875	The prognostic impact of neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio in patients with advanced colorectal cancer treated with first-line chemotherapy. 2018 , 13, 218-222	7
1874	Primary and metastatic malignancies of the lung: Retrospective analysis of the CT-guided high-dose rate brachytherapy (CT-HDRBT) ablation in tumours . 2018 , 108, 230-235	5
1873	Radiofrequency ablation versus resection for technically resectable colorectal liver metastasis: a propensity score analysis. 2018 , 16, 207	22
1872	FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. 2018 , 104, 108-116	13
1871	Personalisierte Therapie von gastrointestinalen Malignomen. 2018 , 21, 37-43	
1870	Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. 2018 , 9, 16477-16488	16
1869	Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival. 2018 , 18, 882	12
1868	BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases. 2018 , 153, 1162-1163	

1867	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. 2018 , 19, 1451-1463	2
1866	Perioperative Management for Colorectal Peritoneal Metastases. 2018 , 17, 249-250	
1865	Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study. 2018 , 7, e1474319	41
1864	The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. 2018 , 144, 2149-2159	6
1863	Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer. 2018 , 30, 269-275	9
1862	Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. 2018 , 3, e000353	30
1861	Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material. 2018 , 41, 1419-1427	4
1860	Colorectal Cancer: Why Does Side Matter?. 2018 , 78, 789-798	26
1859	Pulmonary Thermal Ablation Enables Long Chemotherapy-Free Survival in Metastatic Colorectal Cancer Patients. 2018 , 41, 1727-1734	9
1858	Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. 2018 , 17, 198-205	25
1857	Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review. 2018 , 129, 91-101	31
1856	Regorafenib: A Review in Metastatic Colorectal Cancer. 2018 , 78, 1133-1144	41
1855	Transarterial Embolization with Small-Size Particles Loaded with Irinotecan for the Treatment of Colorectal Liver Metastases: Results of the MIRACLE III Study. 2018 , 41, 1708-1715	9
1854	The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. 2018 , 2018, 9531925	31
1853	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. 2018 , 100, 35-45	20
1852	RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. 2018 , 2018, 4248971	22
1851	Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. 2018 , 20, 664-676	17
1850	AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. 2018 , 17, e631-e637	8

1849	Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial. 2018 , 17, 285-296	27
1848	Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions. 2018 , 232, 72-81	14
1847	The safety of ramucirumab for the treatment of colorectal cancer. 2018 , 17, 945-951	9
1846	Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. 2018 , 16, 3674-3680	8
1845	Clinical update on K-Ras targeted therapy in gastrointestinal cancers. 2018 , 130, 78-91	11
1844	First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. 2018 , 9, 441	6
1843	Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. 2018 , 119, 517-522	20
1842	A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial. 2018 , 7, 4217-4227	10
1841	Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. 2018 , 101, 105-113	14
1840	First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. 2018 , 101, 263-272	38
1839	The Purified Extract from the Medicinal Plant , Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis. 2018 , 7,	31
1838	Comparison of guidelines for the management of rectal cancer. 2018 , 2, 433-451	27
1837	Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance. 2017 , 8, 1886	7
1836	A large-scale and robust dynamic MRM study of colorectal cancer biomarkers. 2018 , 187, 80-92	12
1835	Liquid Biopsy in Colorectal Cancer-Current Status and Potential Clinical Applications. 2018 , 9,	21
1834	Probing the colorectal cancer proteome for biomarkers: Current status and perspectives. 2018 , 187, 93-105	31
1833	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. 2018 , 119, 303-312	17
1832	Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. <i>Annals of Oncology</i> , 2018 , 29, 1955-1963	31

1831	Targeted therapy for metastatic colorectal cancer. 2018 , 18, 991-1006	31
1830	Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position. <i>Annals of Oncology</i> , 2018 , 29, 1893-1894	10.3 4
1829	Preoperative Selection and Optimization for Liver Resection in Colorectal Cancer Liver Metastases. 2018 , 14, 89-97	
1828	Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study. 2018 , 144, 2001-2010	13
1827	Nanotheranostics and Their Potential in the Management of Metastatic Cancer. 2018 , 199-244	2
1826	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. 2018 , 130, 13-26	20
1825	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. 2018 , 3, e000403	15
1824	Cell-free DNA and chemoembolization in patients with liver metastases from colorectal cancer. 2018 , 16, 2654-2660	6
1823	Novel Systemic Therapies for Advanced Gastric Cancer. 2018 , 18, 1-19	25
1822	Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. 2018 , 37, 57	92
1821	Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation. 2018 , 28, 4735-4747	34
1820	The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. 2018 , 17, 643-650	2
1819	First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials. 2018 , 3, 85-86	3
1818	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. 2018 , 14, 2437-2459	5
1817	Colorectal cancer liver metastases - a population-based study on incidence, management and survival. 2018 , 18, 78	268
1816	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. 2018 , 18, 98	6
1815	The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. 2018 , 18, 283	71
1814	Local therapy of stage IV renal cell cancer: a case report. 2018 , 11, 38-42	0

1813	Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. 2018 , 8, 7386	7
1812	Managing Synchronous Liver Metastases in Colorectal Cancer. 2018 , 9, 461-471	2
1811	Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. 2018 , 119, 605-614	15
1810	Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first?. 2018 , 10, 1758835918787993	7
1809	Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. 2018 , 44, 1685-1702	58
1808	Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer. 2018 , 214, 1621-1625	6
1807	A radiologist's point of view in the presurgical and intraoperative setting of colorectal liver metastases. 2018 , 14, 2189-2206	18
1806	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. 2018 , 19,	1
1805	Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. 2018 , 17, 2164-2175	22
1804	Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study). 2018 , 23, 919-927	5
1803	Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. 2018 , 11, 4233-4246	12
1802	Dual-energy CT in patients with colorectal cancer: Improved assessment of hypoattenuating liver metastases using noise-optimized virtual monoenergetic imaging. 2018 , 106, 184-191	19
1801	Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. 2018 , 10, 2289-2301	16
1800	Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. 2018 , 17, e733-e739	5
1799	Radiation Therapy in Rectal Cancer. 2018 , 1-21	
1798	Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer. 2018 , 103, 1369-1375	14
1797	Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition. 2018 , 109, 2074-2079	8
1796	Magnolin promotes autophagy and cell cycle arrest via blocking LIF/Stat3/Mcl-1 axis in human colorectal cancers. 2018 , 9, 702	24

1795	Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib. 2018 , 17, 274-279	12
1794	[Oligometastasized colorectal cancer-modern treatment strategies]. 2018 , 89, 497-504	
1793	Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study. 2018 , 13, e0190497	7
1792	The Effect of Telephone-Based Follow-Up on Adherence, Efficacy, and Toxicity of Oral Capecitabine-Based Chemotherapy. 2019 , 25, 462-470	12
1791	Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer. 2019 , 144, 841-847	12
1790	Successful desensitization of a patient with cetuximab hypersensitivity: A case report. 2019 , 25, 1726-1730	3
1789	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in Wild-Type Metastatic Colorectal Cancer. 2019 , 25, 134-141	28
1788	Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CTâ-derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer. 2019 , 60, 178-184	13
1787	SIR-Spheresâ Y-90 resin microspheres in chemotherapy refractory or intolerant patients with metastatic colorectal cancer. 2019 , 2019, 228424031984744	
1786	Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. 2019 , 106, 1837-1846	16
1785	Oligometastasierung beim kolorektalen Karzinom âmoderne Therapiekonzepte. 2019 , 41, 194-201	
1784	Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. 2019 , 9, 11542	13
1783	Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. 2019 , 19, 267-275	1
1782	Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases. 2019 , 404, 527-539	8
1781	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality.. 2019 , 3, 1-14	6
1780	Value of tumor size as a prognostic factor in metastatic colorectal cancer patients after chemotherapy: a population-based study. 2019 , 15, 1745-1758	10
1779	Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer. 2019 ,	0
1778	Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital. 2019 , 11,	8

1777	ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. 2019 , 18, 280-291.e5	11
1776	Nanotechnology-based siRNA delivery strategies for metastatic colorectal cancer therapy. 2019 , 568, 118530	15
1775	How to increase the resectability of initially unresectable colorectal liver metastases: A surgical perspective. 2019 , 3, 476-486	19
1774	Roles of exosomes in metastatic colorectal cancer. 2019 , 317, C869-C880	16
1773	Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM). 2019 , 45, 2310-2315	3
1772	Beppu's Nomogram Score Is an Independent Prognostic Factor for Colorectal Liver Metastasis Receiving Perioperative Chemotherapy and/or Targeted Therapy. 2019 , 33, 1301-1306	3
1771	Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. 2019 , 11,	11
1770	Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases. 2019 , 20, 1767-1775	6
1769	The difference in prognosis of stage II and III colorectal cancer based on preoperative serum tumor markers. 2019 , 10, 3757-3766	10
1768	Liver-Directed and Systemic Therapies for Colorectal Cancer Liver Metastases. 2019 , 42, 1240-1254	5
1767	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. 2019 , 79, 1375-1394	29
1766	Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. 2019 , 45, 2340-2346	9
1765	Diagnostic performance of gadoxetic acid-enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection. 2019 , 19, 129	32
1764	Microarray Approach Combined with ddPCR: An Useful Pipeline for the Detection and Quantification of Circulating Tumour dna Mutations. 2019 , 8,	6
1763	Exploring the best treatment options for BRAF-mutant metastatic colon cancer. 2019 , 121, 434-442	26
1762	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. 2019 , 121, 378-383	2
1761	Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation. 2019 , 14, e0219204	11
1760	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. 2019 , 5, 1268-1275	37

1759	Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer. 2019 , 39, 825-834	9
1758	Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?. 2019 , 42, 1213-1220	7
1757	A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer. 2019 , 97, 211-216	4
1756	A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis. 2019 , 145, 2313-2323	7
1755	Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study. 2019 , 145, 2357-2363	11
1754	Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat?. 2019 , 11,	10
1753	Secondary non-resectable liver tumors: A single-center living-donor and deceased-donor liver transplantation case series. 2019 , 18, 412-422	6
1752	MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer. 2019 , 34, 1871-1877	5
1751	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. 2019 , 11,	17
1750	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. 2019 , 9, 849	67
1749	FOLFOXIRI Plus Panitumumab As First-Line Treatment of Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). 2019 , 37, 3401-3411	67
1748	What Should We Do Better? Lessons from Negative Results of a Biomarker Validation Study. 2019 , 111, 754-756	
1747	Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer. 2019 , 9, 1080	9
1746	Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. 2019 , 19, 1030	14
1745	MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. 2019 , 106, 119-128	34
1744	Electromagnetic navigation system combined with High-Frequency-Jet-Ventilation for CT-guided hepatic ablation of small US-Undetectable and difficult to access lesions. 2019 , 36, 1051-1057	6
1743	DNA repair capacity and response to treatment of colon cancer. 2019 , 20, 1225-1233	5
1742	Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. 2019 , 9, 16894	4

1741	Novel chemotherapeutic agent, FND-4b, activates AMPK and inhibits colorectal cancer cell proliferation. 2019 , 14, e0224253	2
1740	Multicentre study of perioperative adjuvant chemotherapy for resectable colorectal liver metastases. 2019 , 3, 678-686	7
1739	Radioembolization in liver tumors. 2019 , 38, 370-381	
1738	Dimethylfumarate Inhibits Colorectal Carcinoma Cell Proliferation: Evidence for Cell Cycle Arrest, Apoptosis and Autophagy. 2019 , 8,	13
1737	Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis. 2019 , 12, 300-312	5
1736	Diagnostic and Prognostic Value of Hypermethylation and Its Clinical Significance as a Novel Circulating Cell-Free DNA Biomarker in Colorectal Cancer. 2019 , 11,	18
1735	The global challenge of colorectal cancer. 2019 , 4, 894-895	28
1734	Spatial heterogeneity of mutations in colorectal cancers in northern France. 2019 , 11, 8337-8344	3
1733	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. 2019 , 11,	2
1732	Konsensus zu den "Tumorboard Essentials" beim metastasierten kolorektalen Karzinom. 2019 , 17, 38-42	
1731	MiRNAs roles in the diagnosis, prognosis and treatment of colorectal cancer. 2019 , 16, 851-856	15
1730	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. 2019 , 19, 857	46
1729	Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer. 2019 , 11, 390-396	3
1728	Towards Circulating-Tumor DNA-Based Precision Medicine. 2019 , 8,	5
1727	Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials. 2019 , 34, 1741-1747	11
1726	Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. 2019 , 9, 766	12
1725	[Therapeutic regimens using monoclonal antibodies in gastroenterology]. 2019 , 60, 1043-1058	1
1724	A positive feedback loop of β -catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer. 2019 , 10, 643	14

1723	Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. 2019 , 19, 899	8
1722	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. 2019 , 37, 3099-3110	35
1721	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. 2019 , 11, 1758835919874653	18
1720	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. 2019 , 18, 245-256.e5	0
1719	Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma. 2019 , 2, e1911154	7
1718	Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. 2019 , 18, 823-828	16
1717	Colorectal Liver Metastases. 2019 ,	0
1716	Predictive And Prognostic Value Of Hepatic Steatosis In Conversion Therapy For Colorectal Liver-limited Metastases: A Propensity Score Matching Analysis. 2019 , 11, 8315-8326	0
1715	Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. 2019 , 51, 1-15	33
1714	Safety Report of TAS-102 in a Patient With Reduced DPD Activity. 2019 , 18, 310-312	3
1713	Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients. 2019 , 11, 1758835919876196	
1712	Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data. 2019 , 26, 313-322	2
1711	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. 2019 , 92, 20181026	3
1710	Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer. 2019 , 58, 326-333	1
1709	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. 2019 , 19, 455-464	3
1708	Involvement of MAF1 homolog, negative regulator of RNA polymerase III in colorectal cancer progression. 2019 , 54, 1001-1009	6
1707	Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. 2019 , 8, 882-889	21
1706	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. 2019 , 38, 41	37

1705	Angiogenesis in Y-Radioembolization of Colorectal Liver Metastases. 2019 , 49, 204-210	0
1704	Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. <i>Annals of Oncology</i> , 2019 , 30, 439-446	10.3 14
1703	JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. 2019 , 38, 28	12
1702	Current Status of Maintenance Systemic Therapies in Metastatic Colorectal Cancer: 2018 Update. 2019 , 15, 28-35	0
1701	Impact of CEA-targeting Nanoparticles for Drug Delivery in Colorectal Cancer. 2019 , 370, 657-670	6
1700	Treatment sequencing in metastatic colorectal cancer. 2019 , 109, 70-83	99
1699	Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer. 2019 , 29, 3871-3880	6
1698	S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. 2019 , 24, 591-e165	7
1697	Long-Term Outcome After Conventional Two-Stage Hepatectomy Versus Tourniquet-ALPPS in Colorectal Liver Metastases: A Propensity Score Matching Analysis. 2019 , 43, 2281-2289	14
1696	Local treatment of oligometastatic disease: current role. 2019 , 92, 20180835	4
1695	Thermal ablation and systemic therapies in the metastatic liver: time for a "glocal" approach. 2019 , 29, 5042-5044	1
1694	Should Anti-EGFR Agents Be Used in Right-Sided RAS Wild-type Advanced Colorectal Cancer?. 2019 , 15, 130-134	3
1693	Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue. 2019 , 110, 104270	2
1692	In vivo effects of chemotherapy on oncogenic pathways in colorectal cancer. 2019 , 110, 2529-2539	8
1691	Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. 2019 , 17, 100	7
1690	Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. 2019 , 21, 1781-1785	4
1689	BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report. 2019 , 12, 426-429	
1688	Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. 2019 , 9, 8976	26

1687	Bevacizumab in patients treated with palliative colonic stent placement: Is it safe?. 2019 , 90, 125-126	1
1686	Maximising clinical benefit with adequate patient management beyond the second line in mCRC. 2019 , 4, e000495	8
1685	Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial. 2019 , 26, 3561-3567	3
1684	Cardiovascular complications of metastatic colorectal cancer treatment. 2019 , 10, 797-806	7
1683	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. 2019 , 38, 236	12
1682	Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response. 2019 , 10, 470	23
1681	First report on extended distance between tumor lesion and adjacent organs at risk using interventionally applied balloon catheters: a simple procedure to optimize clinical target volume covering effective isodose in interstitial high-dose-rate brachytherapy of liver malignomas. 2019 , 11, 152-161	11
1680	Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. 2019 , 24, e687-e695	14
1679	Performance of prediction models on survival outcomes of colorectal cancer with surgical resection: A systematic review and meta-analysis. 2019 , 29, 196-202	13
1678	Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score. 2019 , 14, e0217411	16
1677	Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program. 2019 , 45, 1870-1875	2
1676	Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases. 2019 , 17, 99	2
1675	Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. 2019 , 16, 157-166	7
1674	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. 2019 , 9, 7665	23
1673	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. 2019 , 114, 128-136	7
1672	Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience. 2019 , 124, 870-876	8
1671	Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. 2019 , 42, 717-725	3
1670	The treatment of rectal cancer with synchronous liver metastases: A matter of strategy. 2019 , 139, 91-95	6

1669	Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. 2019 , 17, 137	9
1668	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. 2019 , 8, 3120-3130	2
1667	Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. 2019 , 18, 159-166.e3	8
1666	and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. 2019 , 11,	32
1665	Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer. 2019 , 8, 3437-3446	7
1664	Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. 2019 , 9, 396	76
1663	Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer. 2019 , 15, 225-230	3
1662	Resectable recurrent colorectal liver metastasis: can radiofrequency ablation replace repeated metastasectomy?. 2019 , 89, 908-913	3
1661	Immunomodulatory Changes Following Isolated RF Ablation in Colorectal Liver Metastases: A Case Report. 2019 , 6,	
1660	Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. 2019 , 475, 39-47	14
1659	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. 2019 , 76, 22-32	131
1658	Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer. 2019 , 25, 213-221	4
1657	Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study. 2019 , 145, 1719-1728	5
1656	Selecting treatment options in refractory metastatic colorectal cancer. 2019 , 12, 2271-2278	16
1655	FOLFOXIRI plus biologics in advanced colorectal cancer. 2019 , 19, 411-422	2
1654	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. 2019 , 11,	3
1653	The "Short-Cut" Laparoscopic Reverse Approach: A Novel Strategy for Synchronous Colorectal Cancer and Liver Metastases Requiring Major or Complex Procedures?. 2019 , 43, 2086-2089	2
1652	Sub-millimeter surgical margin is acceptable in patients with good tumor biology after liver resection for colorectal liver metastases. 2019 , 45, 1551-1558	8

1651	The impact of posthepatectomy liver failure on long-term survival after hepatectomy for colorectal liver metastasis. 2019 , 21, 1185-1193	4
1650	Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer. 2019 , 58, 395-397	1
1649	Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer. 2019 , 15 Suppl 2, 5-13	3
1648	Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization. 2019 , 9, 19	12
1647	Evidence-Based Integration of Yttrium-90 Radioembolization in the Contemporary Management of Hepatic Metastases from Colorectal Cancer. 2019 , 22, 74-80	3
1646	Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life. 2019 , 67, 913-919	0
1645	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. 2019 , 18, 91-101.e3	15
1644	In Vitro Anticancer Efficacy of Six Different Clinically Approved Types of Liquids Exposed to Physical Plasma. 2019 , 3, 588-596	20
1643	Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study. 2019 , 10, 1070-1084	3
1642	Systematic Review of the Prognostic Role of the Immune System After Surgery of Colorectal Liver Metastases. 2019 , 9, 148	5
1641	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. 2019 , 111, 82-93	7
1640	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. 2019 , 18, 845-855	30
1639	Enhanced cytotoxicity of gold porphyrin complexes after inclusion in cyclodextrin scaffolds adsorbed on polyethyleneimine-coated gold nanoparticles. 2019 , 29, 1065-1068	8
1638	Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. 2019 , 105, 243-252	1
1637	Improved visualisation of hepatic metastases in gadoxetate disodium-enhanced MRI: Potential of contrast-optimised (phase-sensitive) inversion recovery imaging. 2019 , 14, e0213408	3
1636	Colorectal liver metastases: An update on multidisciplinary approach. 2019 , 11, 150-172	88
1635	Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. 2019 , 4, 376-388	20
1634	Years of Life Lost for Older Patients After Colorectal Cancer Diagnosis. 2019 , 43, 2077-2085	4

1633	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. 2019 , 25, 3830-3838	23
1632	Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. 2019 , 25, 3954-3961	36
1631	Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer. 2019 , 145, 2488-2495	7
1630	Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. 2019 , 79, 633-645	22
1629	Ramucirumab: the long and winding road toward being an option for mCRC treatment. 2019 , 19, 399-409	3
1628	Local treatment of liver and lung metastases from colorectal cancer: a multicenter Tunisian study. 2019 , 8, CRC08	
1627	Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study. 2019 , 17, 58	8
1626	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. 2019 , 37, 1460-1469	114
1625	BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer. 2019 , 9, 2466	13
1624	Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. <i>Annals of Oncology</i> , 2019 , 30, 520-527	10,3 47
1623	Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC. 2019 , 36, 670-683	2
1622	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. 2019 , 19, 556-563	20
1621	The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with V600E mutation. 2019 , 11, 1758835918820298	6
1620	Disappearing liver metastases: A systematic review of the current evidence. 2019 , 29, 7-13	19
1619	Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation. 2019 , 14, 158-170	7
1618	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. 2019 , 18, 125-132.e2	23
1617	Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma. 2019 , 14, e0212801	10
1616	Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial. 2019 , 145, 1538-1546	36

1615	Precision treatment in colorectal cancer: Now and the future. 2019 , 3, 361-369	17
1614	Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. 2019 , 75, 1-11	30
1613	Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial. 2019 , 49, 339-346	2
1612	Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer. 2019 , 4, e000591	
1611	How we treat metastatic colorectal cancer. 2020 , 4, e000813	20
1610	TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection.. 2019 , 11, 1758835919897543	1
1609	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. 2019 , 4, e000496	0
1608	Pseudo progression in heterogeneity of right-sided metastatic colon carcinoma during nivolumab therapy: A case report. 2019 , 98, e16490	2
1607	Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. 2019 , 24, e450-e457	18
1606	Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial. 2019 , 24, 1180-1187	9
1605	Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. 2019 , 25, 7089-7097	39
1604	[Percutaneous tumor ablation]. 2019 , 48, 1146-1155	6
1603	Perceptions in the management of colorectal peritoneal metastases: A bi-national survey of colorectal surgeons. 2019 , 4, 20190022	1
1602	The Landscape of Actionable Gene Fusions in Colorectal Cancer. 2019 , 20,	17
1601	Mucinous adenocarcinoma of the colon and rectum: A genomic analysis. 2019 , 120, 1427-1435	15
1600	Hepatic metastasis from colorectal cancer. 2019 , 10, 1274-1298	49
1599	Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice. 2019 , 7, 1380-1388	2
1598	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. 2019 , 9, 1102	11

1597	In-Depth Characterization of Mass Spectrometry-Based Proteomic Profiles Revealed Novel Signature Proteins Associated with Liver Metastatic Colorectal Cancers. 2019 , 2019, 7653230	3
1596	Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. 2019 , 9, 17358	40
1595	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. <i>Annals of Oncology</i> , 2019 , 30, 1796-1803	10.3 77
1594	Disappearing colorectal liver metastases: Strategies for the management of patients achieving a radiographic complete response after systemic chemotherapy. 2020 , 121, 848-856	4
1593	Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma. 2019 , 9, 17178	2
1592	Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection. 2019 , 10, 5049-5056	2
1591	The Role of Contrast-Enhanced Imaging for Colorectal Cancer Management. 2019 , 15, 181-189	1
1590	Overall survival of colorectal cancer by stage at diagnosis: Data from the Martinique Cancer Registry. 2019 , 98, e16941	23
1589	History and development of radioembolization: an old idea with modern applications. 2019 , 40, 684-692	3
1588	Ultrasound and Clinical Preoperative Characteristics for Discrimination Between Ovarian Metastatic Colorectal Cancer and Primary Ovarian Cancer: A Case-Control Study. 2019 , 9,	5
1587	Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study. 2019 , 30, 410-415	2
1586	Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience. 2019 , 62, 1195-1203	13
1585	A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. 2019 , 98, e15759	4
1584	Immune Cell Infiltration in the Microenvironment of Liver Oligometastasis from Colorectal Cancer: Intratumoural CD8/CD3 Ratio Is a Valuable Prognostic Index for Patients Undergoing Liver Metastasectomy. 2019 , 11,	7
1583	Sophoridine Inhibits Human Colorectal Cancer Progression via Targeting MAPKAPK2. 2019 , 17, 2469-2479	21
1582	Synchronous isolated splenic metastasis from cancer of hepatic flexure of colon: A case report. 2019 , 98, e15016	3
1581	Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants. 2019 , 8,	6
1580	Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy. 2019 , 11,	18

1579	An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone. 2019 , 30, 428-430	1
1578	Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. 2019 , 24, e990-e1005	149
1577	[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]. 2019 , 106, 759-775	3
1576	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. 2019 , 24, 185-192	52
1575	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. 2019 , 25, 2988-2995	31
1574	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. 2019 , 49, 446-454	5
1573	Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases. 2019 , 18, 8-18	21
1572	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. 2019 , 73, 31-40	9
1571	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. 2019 , 107, 100-114	5
1570	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. 2019 , 73, 41-53	44
1569	Bridge-to-surgery versus emergency surgery in the management of left-sided acute malignant colorectal obstruction - Efficacy, safety and long-term outcomes. 2019 , 51, 364-372	14
1568	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. 2019 , 18, 34-43.e6	5
1567	Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. 2019 , 20, 74-87	57
1566	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. 2019 , 20, 523-534	2
1565	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). 2019 , 21, 46-54	18
1564	Six-transmembrane epithelial antigen of the prostate 1 protects against increased oxidative stress via a nuclear erythroid 2-related factor pathway in colorectal cancer. 2019 , 26, 313-322	10
1563	Do the Oncological and Surgical Outcomes of Young and Older Women Differ in the Treatment of Colorectal Cancer?. 2019 , 28, 258-267	
1562	CT-guided navigated microwave ablation (MWA) of an unfavorable located breast cancer metastasis in liver segment I. 2019 , 14, 146-150	1

1561	Single Nucleotide Polymorphisms in Cancer Research and Treatment. 2019 , 233-242	
1560	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. 2019 , 18, e117-e129	32
1559	Histologically Verified Biliary Invasion was Associated with Impaired Liver Recurrence-Free Survival in Resected Colorectal Cancer Liver Metastases. 2019 , 108, 201-209	5
1558	Expert Consensus Document on Pulmonary Metastasectomy. 2019 , 107, 631-649	77
1557	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. 2019 , 5, 343-350	134
1556	Microsatellite instability and manifestations of angiogenesis in stage IV of sporadic colorectal carcinoma. 2019 , 98, e13956	4
1555	SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer. 2019 , 74, 873-882	25
1554	A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. 2019 , 125, 1629-1636	18
1553	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. 2019 , 42, 159-179	13
1552	Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis. 2019 , 41, 30-41	4
1551	Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece. 2019 , 8, 133-142	6
1550	mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. 2019 , 24, 516-525	14
1549	Nerigoside suppresses colorectal cancer cell growth and metastatic potential through inhibition of ERK/GSK3 β /catenin signaling pathway. 2019 , 57, 352-363	16
1548	Symptoms during chemotherapy in colorectal cancer patients. 2019 , 27, 3007-3017	17
1547	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. 2019 , 145, 576-585	10
1546	Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. 2019 , 119, 489-496	6
1545	Targeting Angiogenesis in Colorectal Carcinoma. 2019 , 79, 63-74	27
1544	CD44v6 engages in colorectal cancer progression. 2019 , 10, 30	54

1543	Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer. 2019 , 11,	24
1542	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. <i>Annals of Oncology</i> , 2019 , 30, 124-131	10,3 29
1541	Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment. 2019 , 18, 28-33.e3	5
1540	Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). 2019 , 10, 143-148	8
1539	Developments in oligometastatic hormone-sensitive prostate cancer. 2019 , 37, 2549-2555	1
1538	The changing face of treatment for metastatic colorectal cancer. 2019 , 19, 61-70	8
1537	Hydrodissection of the Retrohepatic Space: A Technique to Physically Separate a Liver Tumour from the Inferior Vena Cava and the Ostia of the Hepatic Veins. 2019 , 42, 137-144	2
1536	Early-onset colorectal cancer in young individuals. 2019 , 13, 109-131	173
1535	The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center. 2019 , 36, 36-43	19
1534	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. 2019 , 25, 1216-1225	18
1533	Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study. 2019 , 18, e150-e162	2
1532	Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer?. 2019 , 49, 82-89	10
1531	The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases. 2019 , 23, 1957-1963	13
1530	Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience. 2019 , 50, 236-243	4
1529	Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases. 2019 , 188, 43-53	1
1528	Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine. 2020 , 106, 87-94	8
1527	CARving up colorectal cancer organoids in vitro. 2020 , 21, 1-3	3
1526	Modern Surgical Techniques in Cytoreductive Surgery. 2020 , 24, 454-459	3

1525	Survival Benefit of and Indications for Adjuvant Chemotherapy for Resected Colorectal Liver Metastases-a Japanese Nationwide Survey. 2020 , 24, 1244-1260	11
1524	A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. 2020 , 38, 111-119	5
1523	Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review. 2020 , 23, 114-126	4
1522	Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). 2020 , 25, e266-e275	2
1521	The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. 2020 , 20, 15-22	10
1520	Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?. 2020 , 26, 747-753	3
1519	Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM. 2020 , 22, 647-662	24
1518	Rapid clinical mutational testing of , and : a prospective comparative analysis of the Idylla technique with high-throughput next-generation sequencing. 2020 , 73, 35-41	19
1517	Comparative dosimetry between Tc-MAA SPECT/CT and Y PET/CT in primary and metastatic liver tumors. 2020 , 47, 828-837	29
1516	Biomarker-guided therapy for colorectal cancer: strength in complexity. 2020 , 17, 11-32	103
1515	Stenting as a bridge to surgery for obstructed stage IV colorectal cancers - long-term outcomes of a 10-year study. 2020 , 13, 343-350	3
1514	Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers. 2020 , 60, 334-343	18
1513	Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. 2020 , 106, 70-78	8
1512	Salvage RFA in patients with intrahepatic recurrence after major hepatic surgery for colorectal cancer liver metastases: mid-term outcome. 2020 , 30, 1221-1227	4
1511	Feasibility and Safety of CT-Guided High-Dose-Rate Brachytherapy Combined with Transarterial Chemoembolization Using Irinotecan-Loaded Microspheres for the Treatment of Large, Unresectable Colorectal Liver Metastases. 2020 , 31, 315-322	2
1510	The metabolic clinical risk score as a new prognostic model for surgical decision-making in patients with colorectal liver metastases. 2019 , 121, 350	1
1509	Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). 2020 , 27, 98-106	15
1508	Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. 2020 , 21, 321-334	4

1507	Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment. 2020 , 10, 413-424	14
1506	Colorectal cancer peritoneal metastases: Biology, treatment and next steps. 2020 , 46, 675-683	2
1505	Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. 2020 , 27, 877-885	3
1504	Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. 2020 , 147, 1185-1189	14
1503	Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib. 2020 , 25, e75-e84	6
1502	Identification of Two Kinase Inhibitors with Synergistic Toxicity with Low-Dose Hydrogen Peroxide in Colorectal Cancer Cells in vitro. 2020 , 12,	9
1501	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. 2020 , 59, 417-426	11
1500	FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms. 2020 , 9, 1419-1429	11
1499	Diverse Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity. 2020 , 18, 537-548	6
1498	Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. <i>Annals of Oncology</i> , 2020 , 31, 30-40	10.3 58
1497	Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients. 2020 , 35, 273-281	1
1496	Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8-12 years of follow-up. 2020 , 146, 2019-2026	4
1495	Developments in zebrafish avatars as radiotherapy sensitivity reporters - towards personalized medicine. 2020 , 51, 102578	23
1494	Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. 2019 , 12,	35
1493	Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?. 2020 , 35, 295-306	8
1492	Treatment of colorectal cancer in Sub-Saharan Africa: Results from a prospective Nigerian hospital registry. 2019 , 121, 342	7
1491	FDG PET/CT in colorectal cancer. 2020 , 39, 57-66	0
1490	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. 2020 , 35, 1307-1316	4

1489	Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. 2020 , 187, 9-17	7
1488	Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?. 2020 , 18, 287-294	1
1487	Microwave ablation versus resection for colorectal cancer liver metastases - A propensity score analysis from a population-based nationwide registry. 2020 , 46, 476-485	24
1486	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. 2020 , 26, 1372-1384	38
1485	Current status of cancer pharmacogenomics. 2020 , 233-243	
1484	Improved survival after resection of colorectal liver metastases in patients with unresectable lung metastases. 2020 , 22, 368-375	3
1483	High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy: A prospective longitudinal study. 2020 , 44, 101679	11
1482	5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. 2020 , 206, 107447	137
1481	Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Analysis of the VELOUR Trial. 2020 , 26, 717-725	18
1480	Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study. 2020 , 24, 2104-2112	7
1479	Early response evaluation during preoperative chemotherapy for colorectal liver metastases: Combined size and morphology-based criteria predict pathological response and survival after resection. 2019 , 121, 382	7
1478	Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). 2019 , 12,	19
1477	Simultaneous resection of colorectal cancer with synchronous liver metastases; a practice survey. 2020 , 22, 728-734	5
1476	Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report. 2020 , 31, 979-982	2
1475	An Antibody-Tumor Necrosis Factor Fusion Protein that Synergizes with Oxaliplatin for Treatment of Colorectal Cancer. 2020 , 19, 2554-2563	3
1474	Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy. 2020 , 215, 1377-1383	10
1473	DSTYK Promotes Metastasis and Chemoresistance EMT in Colorectal Cancer. 2020 , 11, 1250	7
1472	Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy. 2020 , 12,	1

1471	Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons: A Throw of the Dice?. 2020 , 272, 715-722	18
1470	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. 2020 , 4,	3
1469	The Role of Radiotherapy in the Treatment of Retroperitoneal Lymph Node Metastases from Colorectal Cancer. 2020 , 12, 8913-8921	2
1468	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRODIGE 71 - (FFCD 1710) phase III study. 2020 , 52, 1143-1147	2
1467	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. 2020 , 15, e0239439	3
1466	Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study. 2020 , 10, 1682	3
1465	Anticancer potential of an exopolysaccharide from MB2-1 on human colon cancer HT-29 cells apoptosis induction. 2020 , 11, 10170-10181	7
1464	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. 2020 , 21, 891-898	7
1463	Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naïve KRAS and BRAF wild-type metastatic colorectal cancer. 2020 , 48, 300060520930440	
1462	The characteristics and long-term survival of patients with colorectal liver metastases with pathological complete response after chemotherapy. 2020 , 11, 6256-6263	2
1461	Colorectal Cancer Immunotherapy: Options and Strategies. 2020 , 11, 1624	52
1460	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. 2021 , 107, 353-359	2
1459	Radiomics of Liver Metastases: A Systematic Review. 2020 , 12,	20
1458	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. 2020 , 138, 1-10	9
1457	Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. 2020 , 14, 2894-2919	9
1456	Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. 2020 , 327, 500-511	6
1455	Reliability of digital PCR in detecting KRAS mutation in colorectal cancer using plasma sample: A systematic review and meta-analysis. 2020 , 99, e21171	1
1454	Is Primary Tumor Excision and Specific Metastases Sites Resection Associated With Improved Survival in Stage IV Colorectal Cancer? Results From SEER Database Analysis. 2020 , 86, 499-507	3

1453	Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer. 2020 , 2020, 2351810	
1452	Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. 2020 , 12,	0
1451	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). 2020 , 25, e1855-e1863	12
1450	[Transarterial radioembolization : Immune effects and immuno-oncology]. 2020 , 60, 693-703	1
1449	Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan. 2020 , 27, 3307-3315	10
1448	Surgical management of recurrent colon cancer. 2020 , 11, 513-525	15
1447	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. <i>Annals of Oncology</i> , 2020 , 31, 1135-1147	10.3 27
1446	Modern therapeutic approaches for the treatment of malignant liver tumours. 2020 , 17, 755-772	47
1445	Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer. 2020 ,	78
1444	Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. 2020 , 141, 225-238	10
1443	Recurrence Risk after Radical Colorectal Cancer Surgery-Less Than before, But How High Is It?. 2020 , 12,	8
1442	Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer. <i>Annals of Oncology</i> , 2020 , 31, 1097-1098	10.3
1441	Laparoscopic hepatectomy is safe and effective for the management of patients with colorectal cancer liver metastases in a population-based analysis in Ontario, Canada. A retrospective cohort study. 2020 , 83, 47-52	1
1440	All You Need to Know About Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. 2020 , 16, 793-798	21
1439	Practical considerations in the use of regorafenib in metastatic colorectal cancer. 2020 , 12, 17588359209568626	
1438	Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments. 2020 , 13, 601-617	6
1437	Role of NEU3 Overexpression in the Prediction of Efficacy of EGFR-Targeted Therapies in Colon Cancer Cell Lines. 2020 , 21,	0
1436	The Evolving Roles of as Potential Anti-Cancer Agent: A Review. 2020 , 1-11	2

1435	The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. 2020 , 21,	3
1434	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. 2020 , 383, 2207-2218	455
1433	Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. 2020 , 66, 1510-1520	3
1432	Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer. 2020 , 12,	3
1431	Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies. 2020 , 10, 587692	1
1430	Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. 2020 , 9,	11
1429	Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomes-The University College London Hospital (UCLH) Experience. 2020 , 12,	3
1428	The effect of preoperative chemotherapy on liver regeneration after portal vein embolization/ligation or liver resection in patients with colorectal liver metastasis: a systematic review protocol. 2020 , 9, 279	2
1427	Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. 2020 , 27, e451-e458	3
1426	Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review. 2020 , 15, 262	13
1425	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. 2020 , 8,	4
1424	Prognostic value of tumor infiltrating lymphocytes combined with PD-L1 expression for patients with solitary colorectal cancer liver metastasis. 2020 , 8, 1221	8
1423	Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer. 2020 , 20, 1092	8
1422	Non-coding RNAs and colorectal cancer liver metastasis. 2020 , 475, 151-159	3
1421	Does the presence of an intact primary increase the risk of nonelective colorectal surgery in patients treated with bevacizumab?. 2020 , 22, 1974-1983	
1420	Characterisation of the Expression of Neurotensin and Its Receptors in Human Colorectal Cancer and Its Clinical Implications. 2020 , 10,	2
1419	Small Nucleolar RNA, C/D Box 16 (SNORD16) Acts as a Potential Prognostic Biomarker in Colon Cancer. 2020 , 18, 1559325820917829	4
1418	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. 2020 , 20, 683	26

1417	Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer. 2020 , 86, 277-284	3
1416	Radiological assessment of secondary biliary tree lesions: an update. 2020 , 48, 300060519850398	4
1415	Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer. 2020 , 147, 2891-2901	1
1414	Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer. 2020 , 10, 1115	14
1413	Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. 2020 , 12,	6
1412	Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. 2020 , 21,	10
1411	Controlled pharmacokinetic anti-cancer drug concentration profiles lead to growth inhibition of colorectal cancer cells in a microfluidic device. 2020 , 20, 3167-3178	10
1410	The role of melatonin in colorectal cancer treatment: a comprehensive review. 2020 , 12, 1758835920931714	13
1409	Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review. 2020 , 12, 1758835920940932	2
1408	Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. 2020 , 4, 134-147	2
1407	Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). 2020 , 137, 81-92	1
1406	Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know. 2020 , 7, 100236	5
1405	Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial. 2020 , 12, 1758835920937427	2
1404	Individualized prediction of survival benefit from primary tumor resection for patients with unresectable metastatic colorectal cancer. 2020 , 18, 193	4
1403	Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. 2020 , 146, 2575-2587	8
1402	Advances with pharmacotherapy for peritoneal metastasis. 2020 , 21, 2057-2066	2
1401	The Way Forward to Develop Locoregional Treatments in Oligometastatic Colorectal Cancer. 2020 , 43, 1484-1485	
1400	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. 2020 , 137, 250-259	5

1399	YAP/TAZ Signalling in Colorectal Cancer: Lessons from Consensus Molecular Subtypes. 2020 , 12,	5
1398	Therapeutic Concepts for Oligometastatic Gastrointestinal Tumours. 2020 , 36, 359-363	2
1397	A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. 2020 , 23, 1588-1597	0
1396	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. 2020 , 91, 102112	8
1395	Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients. 2020 , 9, 1832347	13
1394	Factors Associated With Local Tumor Control and Complications After Thermal Ablation of Colorectal Cancer Liver Metastases: A 15-year Retrospective Cohort Study. 2021 , 20, e82-e95	19
1393	Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights. 2021 , 99, 135-143	5
1392	A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective. 2020 , 5, e000850	
1391	The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases. 2020 , 12,	6
1390	From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?. 2020 , 9, 7849-7862	2
1389	Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. 2020 , 4, 224-232	15
1388	Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. 2020 , 151, 280-286	2
1387	Analysis of mutations in circulating tumor DNA and colorectal cancer tissue. 2021 , 96, 376-383	1
1386	Surgery improves the prognosis of colon mucinous adenocarcinoma with liver metastases: a SEER-based study. 2020 , 20, 908	2
1385	Amphiregulin Expression Is a Predictive Biomarker for Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. 2020 , 26, 6559-6567	6
1384	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). 2020 , 9, 1806680	3
1383	Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with -mutated metastatic colorectal cancer: the REVOLUTION study protocol. 2020 , 12, 1758835920929589	4
1382	Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. 2020 , 8, 1407-1425	10

1381	Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. 2020 , 12, 1758835920928635	6
1380	Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. 2020 , 12,	11
1379	Lokale Therapieverfahren beim oligometastasierten kolorektalen Karzinom. 2020 , 26, 869-882	
1378	Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. 2020 , 15, 567-577	5
1377	Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. 2020 , 47, 613-625	5
1376	Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. 2020 , 31, 856-865	0
1375	"Primum Non Nocere" in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications?. 2020 , 10,	2
1374	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. 2020 , 19, 2146-2154	8
1373	Grundlagen der Oligometastasierung und Stellenwert der Lokaltherapie. 2020 , 26, 776-781	1
1372	Colorectal Cancer: Microsatellite Instability/Mismatch Repair Testing in the Era of Digital Pathology. 2020 , 159, 1235-1237	1
1371	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. 2020 , 59, 102923	10
1370	High TKTL1 expression as a sign of poor prognosis in colorectal cancer with synchronous rather than metachronous liver metastases. 2020 , 21, 826-831	2
1369	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. 2020 , JCO2001225	52
1368	The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis. 2020 , 27, 4263-4270	8
1367	Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. 2020 , 12,	2
1366	Long-Term Outcomes in Percutaneous Radiofrequency Ablation for Histologically Proven Colorectal Lung Metastasis. 2020 , 43, 1900-1907	7
1365	Effectiveness and Safety Evaluation of Chinese Medicine in Treatment of Metastatic Colorectal Cancer after Chemotherapy Failure: Protocol of a Prospective Multicenter Cohort Study. 2021 , 27, 674-679	0
1364	Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). 2020 , 138, 19-29	10

1363	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. 2020 , 12,	17
1362	Molecular Targets for the Treatment of Metastatic Colorectal Cancer. 2020 , 12,	14
1361	Romo1 Inhibition Induces TRAIL-Mediated Apoptosis in Colorectal Cancer. 2020 , 12,	3
1360	Effect of trifluridine/tipiracil in patients treated in RECURSE by prognostic factors at baseline: an exploratory analysis. 2020 , 5,	5
1359	Precision Medicine for the Management of Therapy Refractory Colorectal Cancer. 2020 , 10,	1
1358	KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. 2020 , 13, 12601-12613	2
1357	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. 2020 , 11, 600886	11
1356	Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer. 2021 , 20, e75-e81	1
1355	Chemotherapy in combination with resection for colorectal liver metastases â current evidence. 2020 , 3, 100021	1
1354	Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). 2020 , 9, 1848058	3
1353	Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection. 2021 , 9, 443-450	1
1352	Repeated radioembolization in advanced liver cancer. 2020 , 8, 1055	3
1351	Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients. 2020 , 12,	3
1350	Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines. 2020 , 6, 1593-1608	0
1349	Are Microsatellite Patterns Specific for Tumor Types? A Pilot Investigation. 2020 , 1, 3-8	
1348	Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. 2020 , 12,	10
1347	[BRAF V600E-mutant colorectal cancers: Where are we?]. 2020 , 107, 881-895	2
1346	Precision Medicine. 2020 , 36, 407-410	

1345	Efficacy of 90Y-Radioembolization in Metastatic Colorectal Cancer Depending on the Primary Tumor Side. 2021 , 39, 351-357	
1344	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. 2020 , 38, 1774-1783	4
1343	Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. 2020 , 22, 1976-1991	7
1342	Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan. 2020 , 13, 100786	2
1341	Indocyanine Green Clearance Test for the Preoperative Assessment of Chemotherapy-Related Hepatic Injury in Patients with Colorectal Liver Metastasis. 2020 , 12, 3237-3245	1
1340	Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. 2020 , 12,	10
1339	CIRSE Standards of Practice on Thermal Ablation of Liver Tumours. 2020 , 43, 951-962	19
1338	KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. 2020 , 33, 1832-1843	8
1337	Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. 2020 , 12,	37
1336	Preoperative imaging for colorectal liver metastases: a nationwide population-based study. 2020 , 4, 605-621	3
1335	Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. 2020 , 11, 443-460	7
1334	Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer. 2020 , 31, 683-689	5
1333	Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020. 2020 , 11, 1229-1236	4
1332	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. 2020 , 13, 100795	14
1331	The lack of selection criteria for surgery in patients with non-colorectal non-neuroendocrine liver metastases. 2020 , 18, 106	3
1330	Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma. 2020 , 11, 1979-1988	1
1329	Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting. 2020 , 5,	1
1328	Squamous cell anal cancer: Management and therapeutic options. 2020 , 55, 36-46	14

1327	Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy. 2020 , 11, 1052	25
1326	Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. 2020 , 26, 4892-4900	3
1325	Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. 2020 , 15, e0234314	6
1324	Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). 2020 , 19, 285-290	2
1323	Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. 2020 , 25,	13
1322	Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer. 2020 , 16, 89-95	1
1321	A prognostic index model to individually predict clinical outcomes for colorectal cancer with synchronous bone metastasis. 2020 , 11, 4366-4372	3
1320	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. 2020 , 5, e000698	7
1319	Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. 2020 , 12,	2
1318	Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients. 2020 , 9,	2
1317	Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. 2020 , 10, e027665	1
1316	Development and clinical application of bispecific antibody in the treatment of colorectal cancer. 2020 , 16, 689-709	3
1315	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. 2020 , 19, 165-177	6
1314	Electrolyte Disorders Induced by Antineoplastic Drugs. 2020 , 10, 779	12
1313	Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. 2020 , 146, 2077-2087	6
1312	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. 2020 , 37, 565-573	2
1311	Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. 2020 , 19, e110-e116	10
1310	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. 2020 , 27, 2389-2401	7

1309	Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland. 2020 , 43, 237-244	2
1308	Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. 2020 , 6, 414-438	42
1307	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. 2020 , 21, 497-507	98
1306	Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. 2020 , 69, 681-690	42
1305	Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study. 2020 , 146, 1321-1334	2
1304	Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers. 2020 , 21,	5
1303	Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. 2020 , 19, 82-90.e9	1
1302	A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program. 2020 , 10, 522	2
1301	Comprehensive review of targeted therapy for colorectal cancer. 2020 , 5, 22	312
1300	Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer. 2020 , 287, 5236-5248	3
1299	Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey. 2020 , 16, e770-e778	4
1298	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. 2020 , 4,	4
1297	Mucoadhesive-to-penetrating controllable peptosomes-in-microspheres co-loaded with anti-miR-31 oligonucleotide and Curcumin for targeted colorectal cancer therapy. 2020 , 10, 3594-3611	14
1296	Colorectal peritoneal metastases: pathogenesis, diagnosis and treatment options - an evidence-based update. 2020 , 90, 1592-1597	7
1295	Treatment strategies and overall survival for incurable metastatic colorectal cancer - A EURECCA international comparison including 21,196 patients from the Netherlands and Norway. 2020 , 46, 1167-1173	4
1294	Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients. 2020 , 10, 3974	51
1293	A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL. 2020 , 52, 857-861	2
1292	Tumour budding and its clinical implications in gastrointestinal cancers. 2020 , 123, 700-708	6

1291	Methylation-Based Therapies for Colorectal Cancer. 2020 , 9,	11
1290	Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. 2020 , 9, 1773205	1
1289	Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC). 2020 , 10, 964	5
1288	Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. <i>Annals of Oncology</i> , 2020 , 31, 1160-1168 ^{10,3}	21
1287	Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center. 2020 , 34, 2061-2066	
1286	Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan. 2020 , 42, 1376-1387	3
1285	Impact of Site-Specific Metastases on Surgical Value and Survival among Metastatic Colorectal Cancer Patients. 2020 , 86, 220-227	4
1284	ALPPS versus two-stage hepatectomy for colorectal liver metastases--a comparative retrospective cohort study. 2020 , 18, 140	11
1283	Primary Tumor Location Is a Prognostic Factor for Intrahepatic Progression-Free Survival in Patients with Colorectal Liver Metastases Undergoing Portal Vein Embolization as Preparation for Major Hepatic Surgery. 2020 , 12,	3
1282	The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A protocol for systematic review and meta-analysis. 2020 , 99, e20708	1
1281	Survival outcome of palliative primary tumor resection for colorectal cancer patients with synchronous liver and/or lung metastases: A retrospective cohort study in the SEER database by propensity score matching analysis. 2020 , 80, 135-152	4
1280	Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group. 2020 , 12,	28
1279	Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. 2020 , 42, 1361-1375	2
1278	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. 2020 , 135, 230-239	6
1277	Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants. 2020 , 2, 329-332	2
1276	Is It Time to Introduce PET/CT in Colon Cancer Guidelines?. 2020 , 45, 525-530	3
1275	miRNAs-Based Molecular Signature for Mutated and Wild Type Colorectal Cancer: An Explorative Study. 2020 , 2020, 4927120	8
1274	Prognostic Heterogeneity of MRE11 Based on the Location of Primary Colorectal Cancer Is Caused by Activation of Different Immune Signals. 2019 , 9, 1465	3

1273	Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis. 2020 , 22, 1482-1495	17
1272	RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer. 2020 , 216, 152898	4
1271	CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours. 2020 , 43, 667-683	27
1270	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. 2020 , 19, 187-204	1
1269	Factors related to short-term outcomes and delayed systemic treatment following primary tumor resection for asymptomatic stage IV colorectal cancer. 2020 , 35, 837-846	4
1268	Interventional Radiology for Colorectal Liver Metastases. 2020 , 16, 29-37	2
1267	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. 2020 , 59, 395-403	3
1266	Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors. 2020 , 22, 467-475	3
1265	Laparoscopic Versus Open Thermal Ablation of Colorectal Liver Metastases: A Propensity Score-Based Analysis of Local Control of the Ablated Tumors. 2020 , 27, 2370-2380	3
1264	Telomere maintenance in interplay with DNA repair in pathogenesis and treatment of colorectal cancer. 2020 , 35, 261-271	7
1263	Evolving role of regorafenib for the treatment of advanced cancers. 2020 , 86, 101993	24
1262	A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer. 2020 , 13, 761-768	5
1261	Treatment patterns for metastatic colorectal cancer in Spain. 2020 , 22, 1455-1462	3
1260	Multimorbidity and short-term overall mortality among colorectal cancer patients in Spain: A population-based cohort study. 2020 , 129, 4-14	14
1259	Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis. 2020 , 146, 545-553	9
1258	Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. 2020 , 15, 193-201	3
1257	Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). 2020 , 19, 109-115	5
1256	First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. 2020 , 16, 21-29	16

1255	FDG PET/CT in colorectal cancer. 2020 , 39, 57-66	2
1254	Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer. 2020 , 15, e0227294	4
1253	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. 2020 , 6, 111-129	6
1252	Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. 2020 , 9,	27
1251	How to Best Image Colorectal Liver Metastases. 2020 , 16, 11-17	2
1250	Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. 2020 , 59, 475-483	16
1249	A meta-analysis of liver-first versus classical strategy for synchronous colorectal liver metastases. 2020 , 35, 537-546	3
1248	High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. 2020 , 19, e26-e47	11
1247	TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. 2020 , 21, 412-420	69
1246	Zebrafish Avatars towards Personalized Medicine-A Comparative Review between Avatar Models. 2020 , 9,	29
1245	Laparoscopic colorectal resection combined with simultaneous thermal ablation or surgical resection of liver metastasis: a retrospective comparative study. 2020 , 37, 137-143	0
1244	Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel Sequencing for Detecting and Quantifying Circulation Tumor DNA in Colorectal Cancer Patients. 2020 , 38, 85-93	6
1243	Comparison of sequential, delayed and simultaneous resection strategies for synchronous colorectal liver metastases. 2020 , 20, 16	4
1242	and Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. 2020 , 9,	19
1241	Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. 2020 , 9, 1779-1789	4
1240	Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). 2020 , 52, 493-505	6
1239	ADAMTS8 is frequently down-regulated in colorectal cancer and functions as a tumor suppressor. 2020 , 524, 663-671	9
1238	Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. 2020 , 16 Suppl 1, 3-12	1

1237	Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway. 2020 , 11, 814	39
1236	Therapiesequenz beim metastasierten kolorektalen Karzinom. 2020 , 23, 15-21	
1235	Perioperative Therapie des CRC. 2020 , 23, 10-14	
1234	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. 2020 , 86, 102020	4
1233	Evaluation of , and mutational status and microsatellite instability in early colorectal carcinomas invading the (pT1): towards an in-house molecular prognostication for pathologists?. 2020 , 73, 741-747	6
1232	The Role of Anti-Angiogenics in Pre-Treated Metastatic -Mutant Colorectal Cancer: A Pooled Analysis. 2020 , 12,	9
1231	Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer. 2020 , 146, 1427-1440	9
1230	Bevacizumab (Avastin®) in cancer treatment: A review of 15'years of clinical experience and future outlook. 2020 , 86, 102017	205
1229	Simultaneous versus staged resection for synchronous colorectal liver metastases: A population-based cost analysis in Ontario, Canada - Health economic evaluation. 2020 , 78, 75-82	4
1228	Performance of a New Blunt-Tip Needle for the Displacement of Critical Structure in Thermal Ablation. 2020 , 43, 924-930	1
1227	Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases. 2020 , 20, 246	27
1226	Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin. 2020 , 15, 2119-2129	13
1225	[Treatment of colorectal and non-colorectal liver metastases: rationale for neoadjuvant therapeutic concepts]. 2020 , 91, 396-404	
1224	Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis. 2020 , 15, e0230914	7
1223	Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study. 2020 , 12, 21-33	2
1222	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. 2020 , 147, 2303-2315	7
1221	Optimizing intraperitoneal drug delivery. 2020 , 197-214	2
1220	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. 2020 , 19, 191-199.e6	10

1219	Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. 2020 , 46, 1925-1931	3
1218	Liver transplantation for colorectal liver metastases: What do we need to know?. 2020 , 82S, 87-92	3
1217	MR-guided microwave ablation in hepatic malignancies: clinical experiences from 50 procedures. 2020 , 37, 349-355	9
1216	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. 2020 , 26, 4107-4119	30
1215	Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. 2020 , 26, 1555-1562	4
1214	Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit. 2020 , 18, 65	
1213	Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. 2020 , 12,	6
1212	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. 2020 , 86, 102023	19
1211	Can Dual-energy CT-based Virtual Monoenergetic Imaging Improve the Assessment of Hypodense Liver Metastases in Patients With Hepatic Steatosis?. 2021 , 28, 769-777	4
1210	Integrated bioinformatics identifies the dysregulation induced by aberrant gene methylation in colorectal carcinoma. 2021 , 8, 521-530	2
1209	Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). 2021 , 70, 114-126	20
1208	Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. 2021 , 87, 905-915	2
1207	Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study. 2021 , 23, 122-129	0
1206	Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report. 2021 , 27, 480-484	3
1205	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review. 2021 , 44, 221-228	0
1204	Prognostic prediction of resectable colorectal liver metastasis using the apparent diffusion coefficient from diffusion-weighted magnetic resonance imaging. 2021 , 5, 252-258	
1203	Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. 2021 , 37, 59-70	1
1202	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. 2021 , 124, 587-594	18

1201	Can medical imaging identify the histopathological growth patterns of liver metastases?. 2021 , 71, 33-41	9
1200	Chemotherapy at the End of Life. 2021 , 36, 73-77	3
1199	A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments. 2021 , 87, 271-283	4
1198	Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. 2021 , 148, 296-306	16
1197	Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. 2021 , 148, 1575-1585	7
1196	Simultaneous approach for patients with synchronous colon and rectal liver metastases: Impact of site of primary on postoperative and oncological outcomes. 2021 , 47, 842-849	2
1195	Diagnostic and therapeutic algorithm for colorectal peritoneal metastases. A consensus of the peritoneal surface malignancies onco-team of the Italian society of surgical oncology. 2021 , 47, 164-171	1
1194	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. 2021 , 124, 183-190	5
1193	The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis. 2021 , 44, 50-62	4
1192	Curcumin: A therapeutic strategy for colorectal cancer?. 2021 , 73, 321-330	8
1191	Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. 2021 , 28, 3332-3342	5
1190	An appraisal of emerging second line therapies for metastatic colorectal cancer. 2021 , 15, 165-179	0
1189	Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. 2021 , 26, 111-117	6
1188	Impact of Primary Tumor Location on Survival After Curative Resection in Patients with Colon Cancer: A Meta-Analysis of Propensity Score-Matching Studies. 2021 , 26, 196-207	1
1187	Peritoneal carcinomatosis from colorectal cancer in the pediatric population: Cytoreductive surgery and HIPEC. A systematic review. 2021 , 47, 211-215	1
1186	Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial. 2021 , 10, 454-461	5
1185	Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization-a prospective, within-patient randomized study. 2021 , 48, 1658-1668	2
1184	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. 2021 , 92, 102135	2

- 1183 Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. **2021**, 28, 1532-1547 2
- 1182 Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience. **2021**, 26, e597-e602 5
- 1181 Outcomes following potentially curative therapies for older patients with metastatic colorectal cancer. **2021**, 47, 591-596
- 1180 Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. **2021**, 40, 82-90 0
- 1179 Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155. **2021**, 148, 1948-1963 4
- 1178 Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. **2021**, 26, e261-e269 3
- 1177 Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. **2021**, 28, 1-25 7
- 1176 The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. **2021**, 124, 797-804 4
- 1175 Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. **2021**, 44, 29-40 3
- 1174 Analysis of failed therapy evaluations in radioembolization of primary and secondary liver cancers. **2021**, 147, 1537-1545 1
- 1173 Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. **2021**, 124, 176-182 5
- 1172 Systemische Therapie des metastasierten Kolonkarzinoms. **2021**, 27, 259-266
- 1171 Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer. **2021**, 478, 695-705 1
- 1170 Interdisziplinäres Management bei synchron (oligo)metastasierten gastrointestinalen Tumoren zur Verhinderung von therapieassoziierten Nebenwirkungen. **2021**, 27, 332-342
- 1169 Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer. **2021**, 112, 296-304 3
- 1168 Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. **2021**, 102, 19-26 2
- 1167 Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. **2021**, 27, 120-130 11
- 1166 A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). **2021**, 26, 399-408 2

1165	Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. 2021 , 87, 31-41	0
1164	Controversies in the treatment of RAS wild-type metastatic colorectal cancer. 2021 , 23, 827-839	1
1163	New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. 2021 , 15, 65-79	1
1162	Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). 2021 , 44, 21-35	14
1161	Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer. 2021 , 52, 784-787	
1160	Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. 2021 , 44, 36-49	4
1159	Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study. 2021 , 26, e403-e413	6
1158	Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore. 2021 , 7, 27-41	9
1157	Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. 2021 , 36, 131-139	1
1156	Yttrium-90 radiation segmentectomy for hepatic metastases: A multi-institutional study of safety and efficacy. 2021 , 123, 172-178	9
1155	Past, present, and future perspectives of pulmonary metastasectomy for patients with advanced colorectal cancer. 2021 , 51, 204-211	4
1154	Narrative review of the role of yttrium-90 selective internal radiation therapy in the surgical management of colorectal liver metastases. 2021 , 12, 2438-2446	
1153	C�ncer colorrectal. 2021 , 13, 1335-1344	0
1152	Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. 2021 , 13, 1758835921989223	0
1151	What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?. 2021 , 9, 7	5
1150	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. 2021 , 12, 460-466	2
1149	Interventional Image-Guided HDR Brachytherapy as a Salvage Treatment: Exclusive or in Combination with Other Local Therapies. 2021 , 201-217	
1148	Ablation of Liver Metastases by Brachytherapy. 2021 , 105-115	

1147	Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX. 2021 , 13,	9
1146	Hepatic and Extrahepatic Colorectal Metastases Have Discordant Responses to Systemic Therapy. Pathology Data from Patients Undergoing Simultaneous Resection of Multiple Tumor Sites. 2021 , 13,	2
1145	First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview. 2021 , 10,	1
1144	Stromal Protein-Mediated Immune Regulation in Digestive Cancers. 2021 , 13,	5
1143	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. 2021 , 40, 15	6
1142	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. 2021 , 29, 3971-3980	3
1141	The primary tumor location in colorectal cancer: A focused review on its impact on surgical management.. 2021 , 3, 386-393	2
1140	The Evolutionary Landscape of Treatment for Mutant Metastatic Colorectal Cancer. 2021 , 13,	12
1139	MRI-guided percutaneous thermoablation as first-line treatment of recurrent hepatic malignancies following hepatic resection: single center long-term experience. 2021 , 38, 1401-1408	
1138	Evolutions of the Management of Colorectal Cancer Liver Metastasis: A Bibliometric Analysis. 2021 , 12, 3660-3670	3
1137	Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer. 2021 , 46, 2833-2838	4
1136	PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. 2022 , 71, 119-128	13
1135	Long-term outcomes of ultrasound-guided percutaneous microwave ablation versus resection for colorectal cancer liver metastases: a propensity-score matched study. 2021 , 38, 1276-1284	0
1134	PET/CT imaging in colorectal carcinoma. 2021 ,	
1133	Oral drugs in the treatment of metastatic colorectal cancer. 2021 , 13, 17588359211009001	9
1132	Intraperitoneale intraoperative Chemotherapie (HIPEC/PIPAC). 2021 , 1-13	
1131	An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis. 2021 , 10, 1901464	1
1130	Einfluss und Toxizität perioperativer Therapien auf die onkologische Chirurgie. 2021 , 27, 308-320	

- 1129 Hombre de 58 años con estreñimiento y melenas de una semana de evolución. **2021**, 13, 1368.e1-1368.e3
- 1128 Current practice in cancer pharmacotherapy. **2021**, 9-15
- 1127 Kolon. **2021**, 209-270
- 1126 IMAGE QUALITY STUDY OF RADIATION-REDUCED COMBINED CHEST AND ABDOMEN/PELVIS CT COMPARED WITH A STANDARD PROTOCOL. **2021**, 196, 190-198 0
- 1125 Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care. **2021**, 13, 17588359211027837 1
- 1124 Metformin plus Irinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial. **2021**, 124, 1072-1078 8
- 1123 Initial experience with novel Embocure Plus microspheres for transarterial chemoembolization (TACE) of liver metastatic colorectal cancer tumours - a clinical and study. **2021**, 86, e136-e142 1
- 1122 Treatment Approach for Pancreatic Cancer with Peritoneal Dissemination. **2021**, 195-205
- 1121 Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy. **2021**, 36, 767-778 1
- 1120 Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. **2021**, 13, 0
- 1119 Surgical treatment of colorectal liver metastasis. **2021**, 29, 110-115
- 1118 Role of Thermal Ablation in Colorectal Cancer Lung Metastases. **2021**, 13, 1
- 1117 The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. **2021**, 6, 100031 2
- 1116 Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer. **2021**, 1, 0
- 1115 Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study. **2021**, 91, 1196-1202 0
- 1114 Identification and Characterization of Mortaparib-A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms. **2021**, 13, 6
- 1113 Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy Can Benefit the Locally Advanced Rectal Cancer Patients With Clinically Positive Lateral Pelvic Lymph Node. **2020**, 10, 627572 1
- 1112 Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study. **2021**, 123, 1263-1273 2

1111	First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. 2021 , 38, 219-231	2
1110	Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion. 2021 , 22, 677-684	3
1109	Tumor-Selective Immune-Active Mild Hyperthermia Associated with Chemotherapy in Colon Peritoneal Metastasis by Photoactivation of Fluorouracil-Gold Nanoparticle Complexes. 2021 , 15, 3330-3348	10
1108	Impact of a history of metastases or synchronous metastases on survival in patients with locally recurrent rectal cancer. 2021 , 23, 1120-1131	0
1107	Targeting of TP53-independent cell cycle checkpoints overcomes FOLFOX resistance in Metastatic Colorectal Cancer.	2
1106	Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis. 2021 , 21, 116	5
1105	Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?. 2021 , 10,	0
1104	The Role of Percutaneous Ablation in the Management of Colorectal Cancer Liver Metastatic Disease. 2021 , 11,	3
1103	The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care. 2021 , 11, 3923	2
1102	Targeting KRAS in Colorectal Cancer. 2021 , 23, 28	8
1101	Radiogenomics in Colorectal Cancer. 2021 , 13,	8
1100	Prognosis and factors affecting colorectal cancer with ovarian metastasis. 2021 , 73, 391-398	1
1099	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer. 2021 , 112, 1567-1578	1
1098	Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. 2021 , 23, 1520-1528	0
1097	Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation. 2021 , 13,	2
1096	Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. 2021 , 16, e0246160	4
1095	A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy. 2021 , 10, 1535-1544	2
1094	Current advancements and future perspectives of immunotherapy in colorectal cancer research. 2021 , 893, 173819	21

1093	Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. 2021 , 21, 83	4
1092	A Prognostic Nomogram of Colon Cancer With Liver Metastasis: A Study of the US SEER Database and a Chinese Cohort. 2021 , 11, 591009	4
1091	Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients. 2021 , 12,	6
1090	Current status of treatment for colorectal liver metastases in the United Kingdom. 2021 , 10, 116-118	1
1089	Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases. 2021 , 17, 10-22	
1088	Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial. 2021 , 108, 373-379	1
1087	Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. 2021 , 144, 291-301	3
1086	Current Status and Future Direction of Hepatic Radioembolisation. 2021 , 33, 106-116	5
1085	First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II). 2021 , 11, e044811	1
1084	Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer. 2021 , 13,	2
1083	Perspectives in the Treatment of or Mutated Metastatic Colorectal Cancer Patients. 2021 , 11, 602596	1
1082	Targeting in Cancer: Promising Therapeutic Strategies. 2021 , 13,	8
1081	Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center. 2021 , 12, 487316	1
1080	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. 2021 , 16, 309-324	2
1079	Systematic Review of Treatments for Colorectal Metastases in Elderly Patients to Guide Surveillance Cessation Following Hepatic Resection for Colorectal Liver Metastases. 2021 , 44, 210-223	4
1078	A new rapid diagnostic system with ambient mass spectrometry and machine learning for colorectal liver metastasis. 2021 , 21, 262	9
1077	Repeated hepatectomy after ALPPS for recurrence of colorectal liver metastasis: the edge of limits?. 2021 , 23, 1488-1495	
1076	Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: prospective study. 2021 , 108, 817-825	6

1075	Evolution of Surgical Treatment of Colorectal Liver Metastases in the Real World: Single Center Experience in 1212 Cases. 2021 , 13,	1
1074	Impact of Preanalytical Factors on the Measurement of Tumor Tissue Biomarkers Using Immunohistochemistry. 2021 , 69, 297-320	1
1073	Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging. 2021 , 6, 67-74	1
1072	Prognostic Value of the C-Reactive Protein/Albumin Ratio and Systemic Immune-Inflammation Index for Patients With Colorectal Liver Metastasis Undergoing Curative Resection. 2021 , 27, 633480	4
1071	FIRE-7-Studie (AIO-KRK-0120). 2021 , 36, 244-246	
1070	The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials. 2021 , 13,	8
1069	Prognostic factors of survival in stage IV colorectal cancer with synchronous liver metastasis: Negative effect of the KRAS mutation. 2021 , 14, 93	1
1068	Multimodales Management nichtresektabler Lebermetastasen â neue Therapieoptionen mit Ausblick auf sekundäre Resektion. 2021 , 19, 10-17	
1067	Histopathological and Immune Prognostic Factors in Colo-Rectal Liver Metastases. 2021 , 13,	1
1066	DRP1 Promotes BRAF-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer. 2020 , 10, 592130	1
1065	Frequency of Body Weight Loss is an Independent Prognostic Factor of First-Line Treatment Outcomes in Metastatic Colorectal Cancer. 2021 , 1-7	0
1064	KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer. 2021 , 11, 632962	2
1063	Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases. 2021 , 123, 1773-1783	3
1062	Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers. 2021 , 39, 1315-1323	1
1061	Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer. 2021 , 11, 589673	4
1060	New use for old drugs: Epirubicin in colorectal cancer. 2021 , 60, 954-956	1
1059	Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. 2021 , 40, 82-90	
1058	Locoregional Therapies for Colorectal Cancer Liver Metastases: Options Beyond Resection. 2021 , 41, 133-146	1

1057	The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis. 2021 , 16, e0248775	7
1056	Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. 2021 , 13,	7
1055	Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database. 2021 , 19, 307-318	3
1054	Useful Parameters in Dynamic Contrast-enhanced Ultrasonography for Identifying Early Response to Chemotherapy in a Rat Liver Tumor Model. 2021 , 11, 15	0
1053	T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. 2021 , 73, 726-738	7
1052	Totally laparoscopic simultaneous resection of colorectal cancer and synchronous liver metastases: a single-center case series. 2021 , 1	1
1051	Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome. 2021 , 13,	5
1050	Review of Intra-Arterial Therapies for Colorectal Cancer Liver Metastasis. 2021 , 13,	2
1049	Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review. 2021 , 11, e044239	4
1048	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 2021 , 19, 329-359	153
1047	Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. 2021 , 11, 9080	1
1046	Accuracy of Modern Clinical Risk Score Including RAS Status Changes Based on Whether Patients Received Perioperative Chemotherapy for Colorectal Liver Metastases. 2021 , 45, 2176-2184	0
1045	Case Report-Staged brachytherapy achieving complete metabolic response in unresectable oligometastatic colorectal cancer to the liver. 2021 , 2021, omab016	1
1044	Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. 2021 , 21, 448	2
1043	Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis. 2021 , 19, 97	2
1042	Percutaneous ablation of post-surgical solitary early recurrence of colorectal liver metastases is an effective "test-of-time" approach. 2021 , 73, 1349-1358	2
1041	Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis. 2021 , 21, 188	1
1040	Colorectal Cancer and Immunity: From the Wet Lab to Individuals. 2021 , 13,	1

1039	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. 2021 , 14, 954-963	2
1038	A Novel Prognostic Model and Practical Nomogram for Predicting the Outcomes of Colorectal Cancer: Based on Tumor Biomarkers and Log Odds of Positive Lymph Node Scheme. 2021 , 11, 661040	5
1037	Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. 2021 , 3, 100049	12
1036	Personalized Image-Guided Therapies for Local Malignancies: Interdisciplinary Options for Interventional Radiology and Interventional Radiotherapy. 2021 , 11, 616058	2
1035	Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma. 2021 , 43, 2602-2610	2
1034	Terminal α ,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells. 2021 , 44, 835-850	5
1033	Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review. 2021 , 12, S191-S203	3
1032	Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. 2021 , 13,	1
1031	Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation. 2021 , 81, 849-856	2
1030	Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. 2021 , 26, 1238-1247	0
1029	Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database. 2021 , 17, 1483-1494	4
1028	Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries. 2021 , 17, 1495-1505	0
1027	Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age. 2021 , 13,	1
1026	Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. 2021 , 13,	7
1025	Liver metastases. 2021 , 7, 27	24
1024	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. 2021 ,	1
1023	AIO-FIRE-8-Studie (AIO-KRK/YMO-0519). 2021 , 36, 251-252	
1022	Thermal ablation in colorectal liver metastases-the paradox of equipoise. 2021 , 10, 276-278	

1021	Immune cell infiltration in colonic cancer: correlation between biopsy and surgical specimens. 2021 , 108, 346-350	
1020	Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. 2021 , 6, 100093	1
1019	The Impact of Primary Tumor Resection on Survival in Asymptomatic Colorectal Cancer Patients With Unresectable Metastases. 2021 , 37, 94-100	4
1018	Chemotherapy-Associated Liver Injuries: Unmet Needs and New Insights for Surgical Oncologists. 2021 , 28, 4074-4079	2
1017	A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research. 2021 , 95, 102174	6
1016	Guías de práctica clínica: oportunidad para visibilizar la importancia de la medicina del laboratorio. 2021 , 2, 441-450	
1015	The effectiveness of plasma miR-33a-5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy. 2021 , 21, 489	3
1014	Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. 2021 , 21, 354	0
1013	The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. 2021 , 125, 240-246	2
1012	Centralized multidisciplinary team assessment of metastasis resectability in patients with metastatic colorectal cancer: A fundamental necessity. 2021 , 3, 100058	
1011	Hepatic Radiofrequency Ablation: Monitoring of Ablation-Induced Macrophage Recruitment in the Periablational Rim Using SPION-Enhanced Macrophage-Specific Magnetic Resonance Imaging. 2021 , 56, 591-598	0
1010	Pre-colectomy location and TNM staging of colon cancer by the computed tomography colonography: a diagnostic performance study. 2021 , 19, 120	3
1009	Precision oncology in metastatic colorectal cancer - from biology to medicine. 2021 , 18, 506-525	27
1008	Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art. 2021 , 12, 57	3
1007	Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis. 2021 , 21, 503	
1006	Expression and Prognostic Characteristics of Ferroptosis-Related Genes in Colon Cancer. 2021 , 22,	1
1005	Role of surgical resection and its alternative local therapy for pulmonary metastasis of colorectal cancer. 2021 , 5, 747-753	1
1004	Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients. 2021 , 11, 651380	4

1003	Tc-mebrofenin hepatobiliary scintigraphy and volume metrics before liver preparation: correlations and discrepancies in non-cirrhotic patients. 2021 , 9, 795	0
1002	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial. 2021 , 17, 1923-1931	0
1001	Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study. 2021 , 26, 1477-1484	1
1000	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. 2021 , 22, 665-677	24
999	Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer. 2021 , 11, 651299	0
998	Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. 2021 , 14,	3
997	Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. 2021 , 149, 1385-1397	1
996	The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). 2021 , 47, 2888-2892	6
995	Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. 2021 , 11, 637823	4
994	Safety and efficacy of right portal vein embolization in patients with prior left lateral liver resection. 2021 , 2841851211014192	
993	Perioperative chemotherapy versus surgery alone for resectable colorectal liver metastases: an international multicentre propensity score matched analysis on long-term outcomes according to established prognostic risk scores. 2021 ,	0
992	Relationships Between Ktne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. 2021 ,	1
991	Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy. 41,	
990	Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin. 2021 , 13,	0
989	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. 2021 , 18, e1003620	16
988	Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study. 2021 , 21, 490	2
987	Risk stratification and goal of systemic therapy for successful surgical management of colorectal liver metastases: Oncological optimization. 2021 , 28, 461-469	1
986	MRI Radiomics Signature as a Potential Biomarker for Predicting Status in Locally Advanced Rectal Cancer Patients. 2021 , 11, 614052	2

985	Percutaneous Microwave Ablation Versus Open Surgical Resection for Colorectal Cancer Liver Metastasis. 2021 , 11, 638165	0
984	Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. 2021 , 17, e1846-e1855	1
983	Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. 2021 , 13,	5
982	Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study. 2021 , 35, 445-458	1
981	Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?. 2021 , 33, 351-352	
980	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. 2021 , 39, 1649-1655	1
979	Recurrence at surgical margin following hepatectomy for colorectal liver metastases is not associated with R1 resection and does not impact survival. 2021 , 169, 1061-1068	7
978	Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers. 2021 , 88, 393-402	1
977	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. 2021 , 22, 779-789	53
976	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. 2021 , 13,	6
975	[BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version]. 2021 , 42, 578-590	
974	Is percutaneous destruction of a solitary liver colorectal metastasis as effective as a resection?. 2021 , 25, 198-205	
973	Circulating , , and mRNA in Peripheral Blood and Serum as Potential Biomarkers for Patients with Metastatic Colon Cancer. 2021 , 10,	3
972	Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. 2021 , 10,	3
971	Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. 2021 , 1, 297-310	
970	Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial. 2021 , 299, 470-480	9
969	Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease. 2021 , 87, 3-12	5
968	Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies. 2021 , 160, 1947-1960	7

967	FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. 2021 , 21, 564	3
966	Detection and Clinical Value of Circulating Tumor Cells as an Assisted Prognostic Marker in Colorectal Cancer Patients. 2021 , 13, 4567-4578	6
965	Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. 2021 , 97, 102172	9
964	A novel risk stratification for predicting prognosis of colorectal cancer patients with bone metastasis. 2021 , 12, 933-943	
963	Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. 2021 , 22,	3
962	Dietary Melatonin and Glycine Decrease Tumor Growth through Antiangiogenic Activity in Experimental Colorectal Liver Metastasis. 2021 , 13,	2
961	Prognostic value of metabolic parameters on F-fluorodeoxyglucose positron tomography/computed tomography in classical rectal adenocarcinoma. 2021 , 11, 12947	2
960	Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation. 2021 , 12, 2085-2092	1
959	Newly Obtained Apple Pectin as an Adjunct to Irinotecan Therapy of Colorectal Cancer Reducing Adherence and β -Glucuronidase Activity. 2021 , 13,	6
958	Neoadjuvant Pelvic Radiotherapy in the Management of Rectal Cancer with Synchronous Liver Metastases: Is It Worth It?. 2021 , 25, 2411-2422	1
957	Benefit of intensive chemotherapy for elderly patients aged 80 years or older with metastatic colorectal cancer: a state-wide multicenter cohort study. 2021 , 26, 1248-1256	
956	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. 2021 , 97, 102202	4
955	The Characteristics of 206 Long-Term Survivors with Peritoneal Metastases from Colorectal Cancer Treated with Curative Intent Surgery: A Multi-Center Cohort from PSOGI. 2021 , 13,	2
954	Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer. 2021 , 22, 55	0
953	Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer. 2021 ,	0
952	Strategies to tackle RAS-mutated metastatic colorectal cancer. 2021 , 6, 100156	7
951	Methylome profiling identifies TCHH methylation in CfDNA as a noninvasive marker of liver metastasis in colorectal cancer. 2021 , 35, e21720	1
950	FIRE-9/PORT-Studie (AIO-KRK-0418). 2021 , 36, 323-325	

949	The hallmarks of oligometastatic diseases: Solution for the treatment dilemma. 2021 , 2, 100012	0
948	The Screening and Consensus Based on Practices and Evidence (SCOPE) Program-Results of a Survey on Daily Practice Patterns for Patients with mCRC. 2021 , 28, 2097-2106	1
947	Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.. 2021 , 5, 1082-1087	0
946	The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon. 2021 , 125, 816-825	0
945	Relationship between stromal regulatory T cells and the response to neoadjuvant chemotherapy for locally advanced rectal cancer. 2021 , 1	
944	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. 2021 , 17, 1977-1985	3
943	Virtual Biopsy for Diagnosis of Chemotherapy-Associated Liver Injuries and Steatohepatitis: A Combined Radiomic and Clinical Model in Patients with Colorectal Liver Metastases. 2021 , 13,	3
942	CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC). 2021 , 125, 725-733	1
941	Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. 2021 , 15, 2401-2411	2
940	Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. 2021 , 40, 185	6
939	Predicting Microsatellite Instability Status in Colorectal Cancer Based on Triphasic Enhanced Computed Tomography Radiomics Signatures: A Multicenter Study. 2021 , 11, 687771	5
938	Treatment sequencing of metastatic colorectal cancer based on primary tumor location. 2021 , 48, 119-129	0
937	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. 2021 , 22,	6
936	Contrast Administration Impacts CT-Based Radiomics of Colorectal Liver Metastases and Non-Tumoral Liver Parenchyma Revealing the "Radiological" Tumour Microenvironment. 2021 , 11,	4
935	Liquid biopsy genotyping by a simple lateral flow strip assay with visual detection. 2021 , 1163, 338470	5
934	Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study. 2021 , 13,	3
933	Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. 2021 , 11, 688709	0
932	Oligometastasis scoring system for predicting survival of patients with colorectal liver metastasis after hepatectomy. 2021 , 124, 791-800	

931	The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. 2021 , 6, 100145	8
930	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. 2021 , 27, 4768-4780	5
929	Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial. 2021 , 4, e2118475	3
928	Advanced Deep Learning Approach to Automatically Segment Malignant Tumors and Ablation Zone in the Liver With Contrast-Enhanced CT. 2021 , 11, 669437	3
927	Stereotactic Thermal Ablation of Liver Tumors: 3D Planning, Multiple Needle Approach, and Intraprocedural Image Fusion Are the Key to Success-A Narrative Review. 2021 , 10,	6
926	Newly detected liver nodules with a history of colorectal cancer: are they metastatic? Review of 2,632 cases in a single center. 2021 , 9, 1079	0
925	Successful Case of Treatment the Patient with Synchronous Rectal and Sigmoid Cancers and Synchronous Lung Metastasis. 2021 , 66, 76-81	
924	Clinical impact of PET/MRI in oligometastatic colorectal cancer. 2021 , 125, 975-982	3
923	Liver resection and ablation for squamous cell carcinoma liver metastases. 2021 , 5,	1
922	Significance of preoperative nutritional status as a predictor for short-term and long-term outcomes of patients undergoing surgery for stage IV colorectal cancer. 2021 , 406, 2391-2398	1
921	Liver-First Approach for Synchronous Colorectal Metastases: Analysis of 7360 Patients from the LiverMetSurvey Registry. 2021 , 28, 8198-8208	8
920	Review of chemotherapy-associated paronychia. 2021 ,	1
919	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. 2021 ,	1
918	An opportunity to emphasize the relevance of laboratory medicine. 2021 , 2, 432-440	
917	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. 2021 ,	4
916	Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. 2021 , 22,	3
915	An Exploratory Study on the Stable Radiomics Features of Metastatic Small Pulmonary Nodules in Colorectal Cancer Patients. 2021 , 11, 661763	2
914	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. 2021 , 125, 839-845	2

913	Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. 2021 ,	0
912	RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1. 2021 , 223, 153486	2
911	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. 2021 , 5,	1
910	The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. 2021 , 47, 1661-1667	3
909	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. 2021 , 13,	2
908	Palliative Care in Colorectal Cancer.	
907	Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. 2021 , 11, 15370	1
906	Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR. 2021 , 9,	2
905	Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases. 2022 , 9, HEP40	0
904	Short-Term Outcomes of Secondary Liver Surgery for Initially Unresectable Colorectal Liver Metastases Following Modern Induction Systemic Therapy in the Dutch CAIRO5 Trial. 2021 , 2, e081	2
903	Emerging applications of radiomics in rectal cancer: State of the art and future perspectives. 2021 , 27, 3802-3814	4
902	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). 2021 , 149, 1935-1943	1
901	The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids. 2021 , 16, e0253258	3
900	Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine. 2021 , 8, 693387	1
899	Lung Thermal Ablation: Comparison between an Augmented Reality Computed Tomography (CT) 3D Navigation System (SIRIO) and Standard CT-Guided Technique. 2021 , 10,	0
898	BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options. 2021 , 42, 98-109	0
897	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. 2021 , 98, 102218	7
896	Complete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report. 2021 , 14, 4201-4209	1

- 895 Efficacy of Pelvic Peritoneum Closure After Laparoscopic Extralevator Abdominoperineal Excision for Rectal Cancer. **2021**, 25, 2668-2678 0
- 894 The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer. **2021**, 88, 665-672
- 893 Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naïve patient for BRAF V600E-mutated metastatic colon cancer. **2021**, 152, 1-3 1
- 892 Impact of primary tumor resection on the survival of patients with unresectable colon cancer liver metastasis at different colonic subsites: a propensity score matching analysis. **2021**, 1-16
- 891 Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer. **2021**, 0
- 890 Molecular Determinants and Other Factors to Guide Selection of Patients for Hepatic Resection of Metastatic Colorectal Cancer. **2021**, 22, 82 2
- 889 Colorectal Cancer, Liver Metastases and Biotherapies. **2021**, 9,
- 888 Impact of Primary Tumor Resection on Mortality in Patients with Stage IV Colorectal Cancer with Unresectable Metastases: A Multicenter Retrospective Cohort Study. **2021**, 45, 3230-3239 1
- 887 Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?. **2021**, 5, 477-483 1
- 886 Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). **2021**, 21, 947 0
- 885 A Versatile Theranostic Platform for Colorectal Cancer Peritoneal Metastases: Real-Time Tumor-Tracking and Photothermal-Enhanced Chemotherapy. **2021**, 8, e2102256 3
- 884 Liquid Biopsy Hotspot Variant Assays: Analytical Validation for Application in Residual Disease Detection and Treatment Monitoring. **2021**, 67, 1483-1491 0
- 883 Amelioration of oxidative stress, inflammation and tumor promotion by Tin oxide-Sodium alginate-Polyethylene glycol-Allyl isothiocyanate nanocomposites on the 1,2-Dimethylhydrazine induced colon carcinogenesis in rats. **2021**, 14, 103238 1
- 882 Neoadjuvant chemotherapy for patients with resectable colorectal cancer liver metastases: A systematic review and meta-analysis. **2021**, 9, 6357-6379 1
- 881 Place of regorafenib in treatment of patients with metastatic colorectal cancer: when are all options exhausted? Or in third line?. **2021**, 30-35
- 880 The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis. **2021**, 21, 903 0
- 879 Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. **2021**, 1 1
- 878 Borderline resectable for colorectal liver metastases: Present status and future perspective. **2021**, 13, 756-763 0

877	The What, the Why, and the How of Liver Ablations: A Practical Guide for the Medical Oncologist. 2021 , 99, 722-731	
876	Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis. 2021 , 64, 1074-1082	
875	Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic. 2021 , 23, 256-259	
874	NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature. 2021 , 153, 86-95	2
873	Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. 2021 , 4, e2118416	7
872	The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis. 2021 , 11,	0
871	Development of a model to predict pathologic response to chemotherapy in patients with colorectal liver metastases. 2021 , 12, 1498-1508	2
870	Genetic mutations associated with sensitivity to neoadjuvant chemotherapy in metastatic colon cancer: A case report and review of literature. 2021 , 9, 7099-7109	
869	Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases. 2021 , 70, 103498	3
868	MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories. 2021 , 114, 99-109	3
867	Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule. 2021 , 20, 1977-1987	2
866	Histological tumor response to neoadjuvant chemotherapy correlates to Immunoscore in colorectal cancer liver metastases patients. 2021 , 124, 1431-1441	1
865	Conversion therapy in patients with colorectal liver metastases. 2021 , 47, 2038-2045	2
864	The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up. 2021 , 16, 1840-1849	3
863	The potential use of extended criteria donors and eligible recipients in liver transplantation for unresectable colorectal liver metastases in Central Sweden. 2021 , 10, 476-485	1
862	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. 2021 , 153, 16-26	1
861	Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and H-MR spectroscopy compared with histology (subgroup in the RAXO trial). 2021 , 6, 100208	1
860	Diagnostic Value of Delayed PET/MR in Liver Metastasis in Comparison With PET/CT. 2021 , 11, 717687	0

- 859 Elevated Neutrophil-to-Lymphocyte Ratio in Perioperative Periods is Suggestive of Poor Prognosis in Patients with Colorectal Cancer. **2021**, 14, 4457-4466 1
- 858 Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. **2021**, 40, 288 8
- 857 Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab. **2021**, 22, 783 1
- 856 Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion. 1
- 855 Predicting the Survival and Immune Landscape of Colorectal Cancer Patients Using an Immune-Related lncRNA Pair Model. **2021**, 12, 690530 1
- 854 Very Early Recurrence After Liver Resection for Colorectal Metastases: Incidence, Risk Factors, and Prognostic Impact. **2021**, 1 3
- 853 Utility of exome sequencing in routine care for metastatic colorectal cancer. **2021**, 15, 229 0
- 852 Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. **2021**, 39, 3693-3704 5
- 851 Management of Liver Tumors during the COVID-19 Pandemic: The Added Value of Selective Internal Radiation Therapy (SIRT). **2021**, 10, 0
- 850 Transgelin-2 interacts with CD44 to regulate Notch1 signaling pathway and participates in colorectal cancer proliferation and migration. **2021**, 1 1
- 849 Real-World Outcomes of Oxaliplatin-Based Chemotherapy on R0 Resected Colonic Liver Metastasis. **2021**, 20, e201-e209 1
- 848 Combination of ablation and embolization for intermediate-sized liver metastases from colorectal cancer: what can we learn from treating primary liver cancer?. **2021**, 27, 677-683 1
- 847 Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). **2021**, JCO2101332 8
- 846 Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. **2021**, 4, e2124766 1
- 845 Abnormal Dihydropyrimidine Dehydrogenase Activity as an Indicator of Potential 5-Fluorouracil Linked Cardiotoxicity in Colorectal Cancer Patients: Are Toxic Events Inevitable?. **2021**, 13, e17712 1
- 844 Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers. **2021**, 51, 485-501 3
- 843 Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy. **2021**, 38, 101572 0
- 842 Stereotactic and Robotic Minimally Invasive Thermal Ablation of Malignant Liver Tumors: A Systematic Review and Meta-Analysis. **2021**, 11, 713685 3

841	NTRK fusions in colorectal cancer: clinical meaning and future perspective. 2021 , 25, 677-683	3
840	The prognostic significance of a histological response to preoperative chemotherapy in patients with synchronous colorectal liver metastases.	
839	Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study. 2021 , 11, 728854	3
838	Polysaccharides Synergistically Enhance the Anti-Tumor Efficacy of 5-Fluorouracil Against Colorectal Cancer by Modulating β -Catenin Signaling and Intestinal Flora. 2021 , 12, 736627	2
837	Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature. 2021 , 13, 1043-1061	0
836	Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. 2021 , 20, e173-e184	2
835	Serum Matrix Metalloproteinase-8 and Myeloperoxidase Predict Survival after Resection of Colorectal Liver Metastases. 2021 , 99, 766-779	0
834	Role of salt-inducible kinase 2 in the malignant behavior and glycolysis of colorectal cancer cells. 2021 , 24,	
833	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. 2021 , 13, 143	3
832	Investigation of the Definition of De Novo Oligometastatic Nasopharyngeal Carcinoma: A Retrospective Study. 2021 , 2021, 9977455	
831	Top Ten Tips Palliative Care Clinicians Should Know About Prognostication in Critical Illness and Heart, Kidney, and Liver Diseases. 2021 , 24, 1561-1567	0
830	Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. 2021 , 13,	1
829	A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. 2021 , 17, 3309-3319	1
828	The impact of timely cancer diagnosis on age disparities in colon cancer survival. 2021 , 12, 1044-1051	4
827	Poorly differentiated clusters and tumor budding are important prognostic factors in colorectal carcinomas. 2021 ,	
826	BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases. 2021 , 10, 6998-7011	2
825	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. 2021 , 20, 227-235	2
824	Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy. 2021 , 142, 109863	2

823	Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. 2021 , 22, 1-12	6
822	Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma. 2021 , 2021, 3946875	0
821	Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. 2021 , 20, 265-272	1
820	Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. 2021 , 19, 384	1
819	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. 2021 , 6, 933-946	6
818	The Epidemiology of Lung Metastases. 2021 , 8, 723396	0
817	Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study. 2021 , 16, e0257551	
816	Chemotherapy of metastatic colon cancer in France: A population-based study. 2021 , 53, 1334-1342	0
815	Biosimilars in an era of rising oncology treatment options. 2021 , 17, 3881-3892	0
814	Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. 2021 , 6, 100270	0
813	Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. 2021 , 6, 100246	1
812	The learning curve of laparoscopic ablation of liver tumors: A technically demanding procedure requiring dedicated training. 2021 , 47, 2579-2585	2
811	Multidisciplinary team meetings: are all patients presented and does it impact quality of care and survival - a registry-based study. 2021 , 21, 1032	3
810	mSEPT9 Can Monitor the Response and Predict the Prognosis of Stage IV colorectal cancer Patients with Liver Metastasis Undergoing Potentially Curative Surgery. 2021 , 267, 485-494	1
809	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). 2021 , 157, 71-80	0
808	Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study. 2021 , 14, 101187	0
807	Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer. 2021 , 258-259, 27-36	
806	Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. 2021 , 45, 101607	0

- 805 Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. **2021**, 21, 64 1
- 804 Performance of the Emprint and Amica Microwave Ablation Systems in ex vivo Porcine Livers: Sphericity and Reproducibility Versus Size. **2021**, 44, 952-958 1
- 803 Analysis of first-line treatment in older patients with metastatic colorectal cancer. **2022**, 28, 74-81
- 802 Intraperitoneale intraoperative Chemotherapie (HIPEC/PIPAC). **2021**, 1-13
- 801 Electrocoagulation for liver metastases. **2021**, 1, CD009497
- 800 Treatment of liver metastases in patients with epithelial ovarian cancer. **2021**, 134, 1236-1238
- 799 Image-Guided Brachytherapy in Oligometastasis: Criteria for Patient Selection from an Oncological Perspective. **2021**, 75-89
- 798 Liver Brachytherapy: Experience from Asia. **2021**, 117-128
- 797 Carbon dots for cancer nanomedicine: a bright future. **2021**, 3, 5183-5221 7
- 796 Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases. **2021**, 28, 4744-4755 11
- 795 Composite Score: prognostic tool to predict survival in patients undergoing surgery for colorectal liver metastases. **2021**, 5, 0
- 794 Capecitabine as Maintenance Therapy for High-Risk, Resected Colorectal Cancer. **2021**, 8, 81-86
- 793 Immune Checkpoint Inhibitors as an Armor for Targeted Immunotherapy of Colorectal Cancer. **2021**, 309-326
- 792 Effect of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) and Non-Operative Strategy on Outcomes of Distal Rectal Cancer Patients with Clinically Positive Lateral Pelvic Lymph Node. **2021**, 13, 537-546 0
- 791 Research Strategies for Low-Survival Cancers. **2021**, 13,
- 790 Percutaneous ultrasound guided PEG-coated gold nanoparticles enhanced radiofrequency ablation in liver. **2021**, 11, 1316 1
- 789 [Update of the recommendations for the determination of biomarkers in colorectal carcinoma. National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology]. **2021**, 54, 41-54
- 788 Profiling of host genetic alterations and intra-tumor microbiomes in colorectal cancer. **2021**, 19, 3330-3338 0

787	Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?. 2021 , 28, 100442	5
786	and inhibition as treatment strategies in V600E metastatic colorectal cancer. 2021 , 13, 1758835921992974	5
785	Preoperative Chemotherapy in Peritoneal Metastases of Tumors of the Lower GI Tract Including Appendix Carcinoma. 2021 , 69-77	
784	Metastasis directed therapy for liver and lung metastases from colorectal cancer-A population-based study. 2018 , 143, 3218-3226	14
783	DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation. 2020 , 40, 1108-1129	6
782	Status of Immune Oncology: Challenges and Opportunities. 2020 , 2055, 3-21	5
781	Cell-Free DNA in the Management of Colorectal Cancer. 2020 , 215, 253-261	1
780	FDG PET Hybrid Imaging. 2020 , 216, 625-667	2
779	Oligometastatic Colorectal Cancer Management: A Survey of the Italian College of Interventional Radiology. 2020 , 43, 1474-1483	3
778	Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). 2020 , 146, 2681-2691	3
777	Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer. 2018 , 17, 65-72	9
776	Pattern, Stage, and Time of Recurrent Colorectal Cancer After Curative Surgery. 2019 , 18, e223-e228	31
775	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). 2020 , 19, 301-310.e1	3
774	Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy. 2017 , 34, 116-120	2
773	Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?. 2020 , 32, 310-322	2
772	Pulmonary Metastasectomy in Colorectal Cancer: has the randomized controlled trial brought enough reliable evidence to convince believers in metastasectomy to reconsider their oncological practice?. 2021 , 59, 517-521	4
771	Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients. 2020 , 99, e23719	0
770	Frequent post-treatment monitoring of colorectal cancer using individualized ctDNA validated by multi-regional molecular profiling.	1

769	Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. 2020 , 130, 1199-1216	19
768	Artefact and ablation performance of an MR-conditional high-power microwave system in bovine livers: an ex vivo study. 2019 , 3, 39	2
767	Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases. 2020 , 4, 62	14
766	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 2020 , 38, 1081	48
765	Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases. 2017 , 12, e0179951	28
764	Lycorine Induces autophagy-associated apoptosis by targeting MEK2 and enhances vemurafenib activity in colorectal cancer. 2020 , 12, 138-155	9
763	Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy. 2017 , 8, 37875-37883	11
762	Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis. 2017 , 8, 62339-62348	5
761	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. 2017 , 8, 68305-68316	20
760	Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOCRK0306). 2017 , 8, 105749-105760	35
759	Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis. 2018 , 9, 10272-10283	6
758	and genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. 2018 , 9, 7859-7866	18
757	Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases. 2018 , 9, 27027-27038	16
756	Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach. 2018 , 9, 34279-34288	11
755	Targeting transcription factor TCF4 by EMangostin, a natural xanthone. 2019 , 10, 5576-5591	8
754	[Diagnostic value of F-FDG PET/CT and tumor markers (CEA, CA19-9, CA24-2) in recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma]. 2019 , 51, 1071-1077	1
753	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. 2018 , 4,	2
752	The role of interventional oncology in the treatment of colorectal cancer liver metastases. 2019 , 32, 147-155	18

751	Efficacy and safety of percutaneous computed tomography-guided microwave ablation for colorectal cancer, oligometastatic liver-only disease: a single center's experience. 2021 , 34, 61-67	1
750	Real world aspects of palliative trifluridine plus tiperacil (TAS-102) in refractory metastatic colorectal cancer. 2020 , 11, 616-625	3
749	Metastatic Colorectal Cancer: Prognostic and Predictive Factors. 2020 , 27, 2779-2791	1
748	UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS. 2017 , 4, 122-128	12
747	ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance. 2018 , 15, 127-141	35
746	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. 2019 , 8, e11545	17
745	VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. 2019 , 8, e13696	3
744	Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study. 2020 , 9, e16296	2
743	Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy. 2018 , 19, 2325-2330	2
742	The significance of CO combining power in predicting prognosis of patients with stage II and III colorectal cancer. 2019 , 13, 1071-1080	3
741	From palliation to cure: PIPAC for peritoneal malignancies. 2019 , 110, 385-398	6
740	Immunoscore and its introduction in clinical practice. 2020 , 64, 152-161	22
739	Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients. 2019 , 53, 85-95	5
738	Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision. 2020 , 54, 272-277	5
737	Preliminary results of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in stage II-IV rectal cancer.	2
736	Systemic administration of miRNA mimics by liposomal delivery system in animal model of colorectal carcinoma. 2016 , 65, S481-S488	9
735	Trifluridin/tipiracil in treatment of refractory metastatic colorectal cancer - early clinical experience. 2017 , 11, 88-91	1
734	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. 2020 , 1, 53-70	2

733	CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. 2018 , 24, 4738-4749	57
732	Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance. 2019 , 25, 4383-4404	75
731	Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials. 2019 , 18, 4555-4562	0
730	and mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation. 2021 , 21, 15	3
729	RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer. 2020 , 43, 1853-1862	6
728	Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. 2019 , 34, 1188-1196	3
727	Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?. 2020 , 25, 14	5
726	Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers. 2019 , 8, 92-97	2
725	Standardized Pathology Report for Colorectal Cancer, 2nd Edition. 2020 , 54, 1-19	13
724	Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases. 2019 , 51, 187-193	2
723	Tumor Control and Overall Survival after Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer: A Meta-Analysis. 2020 , 52, 1188-1198	3
722	Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors. 2018 , 10, 528-531	1
721	Predictive factors of histological response of colorectal liver metastases after neoadjuvant chemotherapy. 2019 , 11, 295-309	5
720	Molecular classifications of gastric cancers: Novel insights and possible future applications. 2017 , 9, 194-208	38
719	Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. 2019 , 10, 52-61	13
718	Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. 2019 , 10, 75-85	5
717	Colorectal liver metastases: Current management and future perspectives. 2020 , 11, 761-808	24
716	Przerzuty do otrzewnej raka jelita grubego. 2017 , 89, 34-42	1

715	Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?. 2020 , 11, 68-73	1
714	Resection vs. ablation for lesions characterized as resectable-ablative within the colorectal liver oligometastases criteria: a propensity score matching from retrospective study. 2020 , 8, e8398	2
713	Frameless Single Robotic Radiosurgery for Pulmonary Metastases in Colorectal Cancer Patients. 2020 , 12, e7305	2
712	Characterization of Anti-angiogenic Chemo-sensitization via Longitudinal Ultrasound Localization Microscopy in Colorectal Carcinoma Tumor Xenografts. 2021 , PP,	0
711	The decreased platelet-to-lymphocyte ratio could predict a good prognosis in patients with oligometastatic colorectal cancer: a single-center cohort retrospective study. 2021 , 19, 297	1
710	Characterization of Biomarkers in Colorectal Cancer Liver Metastases as a Prognostic Tool. 2021 , 11,	1
709	Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): study protocol for an international multicentre prospective diagnostic accuracy study. 2021 , 21, 1116	1
708	Long disease-free interval diminishes the prognostic value of primary tumor stage for patients with colorectal cancer liver metastases.. 2021 ,	
707	A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. 2021 , 13,	0
706	The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer. 2021 , 13,	1
705	Neoadjuvant Chemotherapy Followed by Radiofrequency Ablation Prolongs Survival for Ablatable Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study. 2021 , 11, 758552	0
704	Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice. 2021 ,	
703	Colorectal cancer liver metastases: An update of treatment strategy and future perspectives. 2021 , 7, 100042	
702	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes. 2021 , 406, 2797	1
701	Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. 2021 ,	0
700	Radioembolization of Secondary Hepatic Malignancies. 2021 , 38, 445-452	1
699	Impact of the ileal microbiota on colon cancer. 2021 ,	2
698	A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results. 2021 , 1-11	

- 697 Percutaneous Navigation under Local Anesthesia for Computed Tomography-Guided Microwave Ablation of Malignant Liver Lesions Located in the Hepatic Dome. **2021**, 57, 0
- 696 Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. **2021**, 13, 1
- 695 Radioablation of Upper Abdominal Malignancies by CT-Guided, Interstitial HDR Brachytherapy: A Multivariate Analysis of Catheter Placement Assisted by Ultrasound Imaging. **2021**,
- 694 Post-Induction Management in Patients With Left-Sided and Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. **2021**, 11, 712053 3
- 693 Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment.. **2021**, 14, 1475-1482 0
- 692 CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. **2021**, 44, 1851-1867 7
- 691 Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer. **2021**, 21, 554 1
- 690 Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. **2021**, 1
- 689 Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses. **2021**, 164, 236-244 1
- 688 Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie. **2016**, 1-20
- 687 Oligometastases.
- 686 Long-term results of extended and combined surgical interventions in patients with locally advanced rectal cancer in relation to the extent of cytoreduction. **2017**, 6, 21 3
- 685 Uterine metastasis from the rectosigmoid transition cancer: a case report. **2017**, 4, 6
- 684 Long survival in a patient with metastatic colorectal carcinoma: reality or utopia?. **2017**, 109, 667 1
- 683 Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer Samples into Molecular Subtypes.
- 682 Peritoneal metastases of colorectal origin - cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). The financial aspect. **2017**, 89, 1-6
- 681 Immune Checkpoint Inhibitors Against Colon Cancer. **2018**, 71, 406-416
- 680 Lebermetastasen Chirurgie. **2018**, 133-148

679 Leitsymptom. **2018**, 67-100

678 Kolorektales Karzinom. **2018**, 273-341

677 Peritonektomie und HIPEC. **2018**, 291-314

676 Kolon. **2018**, 181-225

675 The Role of Systemic Chemotherapy in Colorectal Cancer. **2018**, 329-343

674 Induktive präoperative Chemotherapie bei peritonealen Metastasen von Tumoren des unteren GI-Trakts inkl. Appendixkarzinom. **2018**, 73-82

673 Kolonkarzinom. **2018**, 203-222

672 Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie. **2018**, 69-87

671 Radioembolization of Hepatic Metastases with 90Y-Microspheres: Indications and Procedure. **2018**, 165-198

670 Development of a prognostic nomogram for metastatic colorectal cancer patients: The study protocol of a multicenter, retrospective, observational, cohort study. **2018**, 26, 116-119

669 TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial (Preprint).

668 TAILORing targeted therapies to the right patient at the right time: how close are we?. **2018**, 6, S87

667 Circulating Tumor DNA in Colorectal Cancer—from Concept to Clinic. **2019**, 15, 33

666 Aufgegeben und doch überlebt. **2019**, 429-433

665 Comparison of the Response Evaluation Criteria in Solid Tumors with Volumetric Measurement for Evaluation of Response and Overall Survival with Liver Metastases from Colorectal Cancer. **2019**, 80, 906

664 Observation of the high efficiency of therapy for metastatic colorectal cancer. **2019**, 8, 366

663 Hepatic resection after neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer: need for cautious planning. **2019**, 97, 245-253

662 Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. **2019**, 407-444

- 661 Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. **2019**, 379-394
- 660 Modern approaches to the diagnosis and surgical treatment of rectal cancer (Review of clinical recommendations). **2019**, 40, 75-81
- 659 Morbidity and Mortality Rates from Digestive Diseases in the RF Northwestern Federal District (NWFD) and Measures to Reduce Them. **2019**, 29, 36-46 6
- 658 VERO_nA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies (Preprint).
- 657 Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial. **2019**, 10, 2791-2792
- 656 L'ADN tumoral circulant dans le cancer colorectal. **2019**, 13, 98-101
- 655 Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer. 1
- 654 The role of PET/CT with 18F-fluorodeoxyglucose in detecting the progression of colorectal cancer in asymptomatic patients with elevated level of carcinoembryonic antigen (literature review). **2019**, 9, 11-15
- 653 Colon and rectal cancer. **2019**, 16, 186-189
- 652 Chemoembolization with CalliSpheres drug-eluting beads loaded with irinotecan in the treatment of unresectable colorectal cancer liver metastases: preliminary results in 16 cases.. **2019**, 8, 856-866
- 651 Resolution on the results of the Expert Council on the treatment of advanced and metastatic clear cell renal cell carcinoma. **2019**, 15, 150-153 1
- 650 Association of Kras mutation with tumor deposit status and overall survival of colorectal cancer.
- 649 An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancer.
- 648 Pancratistatin Inhibits the Growth of Colorectal Cancer Cells by Inducing Apoptosis, Autophagy, and G2/M Cell Cycle Arrest. **2019**, 25, 6015-6022 1
- 647 Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study (Preprint).
- 646 PREDICTORS OF THERAPY RESPONSE AND EARLY RECURRENCE IN PATIENTS WITH POTENTIALLY RESECTABLE COLORECTAL LIVER METASTASES TREATED WITH BEVACIZUMAB AND FOLFOX4 AS A CONVERSION THERAPY. **2019**, 72-79 1
- 645 A pathological complete response by chemotherapy with S-1 and oxaliplatin for a locally advanced duodenal adenocarcinoma in Lynch syndrome: a case report. **2019**, 5, 146 0
- 644 Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population. **2019**, 11, 1031-1042

- 643 Radioembolization in liver tumours. **2019**, 38, 370-381
- 642 Malignant diseases of the hepatobiliary system. **2019**, 173-190
- 641 Conversion Chemotherapy for CRLM-Best Associations, and Does Conversion Translate into Longer Survival?. **2020**, 239-247
- 640 Sequencing of Systemic Chemotherapy for Unresectable CRLM. **2020**, 297-312
- 639 Neoadjuvant Chemotherapy for Resectable Colorectal Cancer Liver Metastases: Indications and Results. **2020**, 205-228
- 638 Adjuvant Chemotherapy for CRLM: Indications and Results. **2020**, 249-258
- 637 Algorithms for Patients with Colorectal Liver Metastasis. **2020**, 145-157
- 636 Diagnosis of Colorectal Liver Metastases. **2020**, 35-48
- 635 The choice of local destruction method of colorectal cancer liver metastases. **2019**, 24, 30-36 2
- 634 Onkologika. **2020**, 671-732 1
- 633 Laparoscopic treatment of mixed adenoneuroendocrine cancer of right colon: case report and review of literature. **2020**, 33,
- 632 Peritumoral activated hepatic stellate cells are associated with hepatic recurrence for resectable colorectal adenocarcinoma liver metastasis following resection. **2020**, 20, 287
- 631 Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases. **2020**, 13, 77 5
- 630 Comparative Analysis of Circulating Biomarkers for Patients Undergoing Resection of Colorectal Liver Metastases. **2021**, 11, 1
- 629 NEOADJUVANT RADIATION THERAPY FOR RECTAL CANCER WITH SYNCHRONOUS LIVER METASTASES (LITERATURE REVIEW). **2021**, 20, 123-137
- 628 Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. **2021**, 21, 1159 1
- 627 Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09. **2021**, 16, 753-760 1
- 626 Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. **2021**, 22, 1

- 625 General insight into cancer: An overview of colorectal cancer (Review). **2021**, 15, 271 9
- 624 PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer. **2020**, 15, e0243997
- 623 Case of rare metastasis of colon cancer. Clinical case. **2020**, 10, 59-64
- 622 How to Write an Operation Record of Complete Cytoreductive Surgery for Colorectal Peritoneal Metastases Utilizing Various Digital Schema. **2020**, 53, 1016-1025
- 621 Oral administration of cytostatic drugs in the treatment of CRC. **2022**, 391-401
- 620 A roadmap for medical treatment of metastatic CRC. **2022**, 365-379
- 619 Population-based universal screening for CRC: Secondary prevention. **2022**, 45-56
- 618 Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future. **2022**, 207-230
- 617 Radiotherapy (stereotactic body radiotherapy) for oligometastatic disease. **2022**, 421-427
- 616 Prognostic and clinic-pathological significances of HOXB8, ILK and FAT4 expression in colorectal cancer. **2020**, 24, 183-192 1
- 615 Comparison of Sequential, Delayed and Simultaneous Resection Strategies for Synchronous Colorectal Liver Metastases.
- 614 Colorectal Cancer: Liver Metastatic Disease. **2020**, 161-179
- 613 Thermal Ablation of Liver Lesions. **2020**, 787-794.e3
- 612 Enteric Type Bartholin Gland Adenocarcinoma: An Unusual Variant of a Rare Neoplasm. **2021**, 40, 190-195 1
- 611 Transcatheter Embolization of Liver Metastases. **2020**, 287-296.e3
- 610 Comparison of Sequential, Delayed and Simultaneous Resection Strategies for Synchronous Colorectal Liver Metastases.
- 609 Multidisziplinäres Tumorboard: sektorenübergreifende Kooperation jenseits gesetzlicher Instrumente. **2020**, 69-83
- 608 Labordiagnostik/Tumormarker: Was ist sinnvoll/effektiv, was wird kommen?. **2020**, 191-207

- 607 Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study. **2021**, 34, 68-72 0
- 606 Complete remission of multiple liver metastases with only partial response of the primary rectal cancer after neoadjuvant chemotherapy. **2020**, 6, 46
- 605 Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions. **2021**, 2
- 604 Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. **2021**, 2
- 603 [Multimodal, interdisciplinary therapeutic concepts for liver metastasized colorectal cancer]. **2021**, 146, 1468-1477
- 602 Baicalein is a novel TLR4-targeting therapeutics agent that inhibits TLR4/HIF-1 α /VEGF signaling pathway in colorectal cancer. **2021**, 11, e564 3
- 601 Computer tomography guided thoracoscopic resection of small pulmonary nodules in the hybrid theatre. **2021**, 16, e0258896 0
- 600 The Ratio of Platelets to Lymphocytes Predicts the Prognosis of Metastatic Colorectal Cancer: A Review and Meta-Analysis. **2021**, 2021, 9699499 1
- 599 Early-onset colorectal cancer: A distinct entity with unique genetic features. **2020**, 20, 33
- 598 Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer. **2020**, 45, 707-708
- 597 Mode of progression after radioembolization in patients with colorectal cancer liver metastases. **2020**, 10, 107 1
- 596 Biology of Liver Tumors and Outcomes of Liver Surgery. **2021**, 303-313
- 595 Liver Metastases. **2021**, 141-174
- 594 The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment. **2021**, 23, 206-212
- 593 Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases. **2020**, 12, 1177-1194 2
- 592 Management of Colorectal Liver Metastases. **2021**, 553-574 0
- 591 Interventional Radiology in Management of Colorectal Carcinoma Metastasis. **2021**, 629-662
- 590 Radiotherapy in Recurrent and Metastatic Rectal Cancer. **2021**, 683-691

- 589 A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer. **2020**, 40, 2
- 588 Incidental Finding of Endobronchial Metastasis by 18F-FDG PET/CT Leads to Change in Management in a Patient With Rectal Adenocarcinoma. **2020**, 45, 980-981 0
- 587 LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study. **2020**, 31, 1084-1090 0
- 586 Introduction to Oncology. **2021**, 159-161
- 585 Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer. **2021**, 187-202
- 584 The actual management of colorectal liver metastases. **2020**, 75, 328-344
- 583 La biopsia líquida en el diagnóstico y monitoreo de pacientes oncológicos: oportunidades y retos en Latinoamérica. **2020**, 24, 164-77
- 582 The impact of timely cancer diagnosis on age disparities in colon cancer survival in New Zealand. 0
- 581 Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review. 0
- 580 Infective endocarditis in a patient with metastatic colorectal cancer. **2018**, 31, 75-77
- 579 A Rare Presentation of Colorectal Cancer with Unusual Progressive Intramuscular and Subcutaneous Metastatic Spread. **2019**, 7, 89-94 2
- 578 has prognostic value in colorectal cancer and represses Warburg effect and cell proliferation via Wnt signaling. **2020**, 10, 1548-1567 6
- 577 Phenoxodiol sensitizes metastatic colorectal cancer cells to 5-fluorouracil- and oxaliplatin-induced apoptosis through intrinsic pathway. **2020**, 19, 936-949
- 576 Photothermal therapy technology of metastatic colorectal cancer. **2020**, 12, 3089-3115 7
- 575 Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. **2020**, 10, 2946-2954 7
- 574 MicroRNA-335 targets the MEK/ERK pathway to regulate the proliferation and metastasis of colon cancer. **2020**, 12, 7899-7907 1
- 573 Elevated LOXL2 expression by LINC01347/miR-328-5p axis contributes to 5-FU chemotherapy resistance of colorectal cancer. **2021**, 11, 1572-1585 1
- 572 Development and validation of survival nomograms in colorectal cancer patients with synchronous liver metastases underwent simultaneous surgical treatment of primary and metastatic lesions. **2021**, 11, 2654-2669

571	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. 2021 , 102, 102301	3
570	Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. 2021 , 526, 41-52	3
569	Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. 2021 , 1	0
568	Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data. 2021 , 13,	0
567	Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach.. 2021 , 12, 1000-1008	3
566	Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. 2021 , 11, 764912	2
565	Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 2021 , 1	1
564	Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist. 2021 , 13,	2
563	Biomarkers of Trifluridine-Tipiracil Efficacy. 2021 , 10,	0
562	Comprehensive Analysis of Subtype-Specific Molecular Characteristics of Colon Cancer: Specific Genes, Driver Genes, Signaling Pathways, and Immunotherapy Responses.. 2021 , 9, 758776	3
561	Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases - a report from the Danish Anal Cancer Group. 2021 , 1-7	
560	Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic oligometastatic colorectal carcinoma (HOLMUS). 2021 , 21, 1232	2
559	Clinical outcomes following colorectal resection of colorectal cancer with simultaneous hepatic and pulmonary metastases at the time of diagnosis. 2021 , 407, 759	0
558	Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?. 2021 , 11, 769305	1
557	Lokale Tumorablation und Selektive Interne Radiotherapie für Patienten mit Metastasierten Neuroendokrinen Tumoren – Interventionelle Tumortherapieverfahren. 2021 , 44, 344-354	0
556	Predictive factors of survival of colorectal cancer patients after para-aortic lymph node metastasis. 2021 , 1	2
555	[Detection of BRAF V600E mutation in metastatic colorectal carcinoma : A QuIP round robin test]. 2021 , 1	
554	DNM1: A Prognostic Biomarker Associated with Immune Infiltration in Colon Cancer-A Study Based on TCGA Database. 2021 , 2021, 4896106	1

553	The impact of DNA testing on management of patients with colorectal cancer.. 2022 , 6, 17-28	0
552	Peroxisporins Are Induced upon Oxidative Stress Insult and Are Associated with Oxidative Stress Resistance in Colon Cancer Cell Lines. 2021 , 10,	3
551	Pharmacoeconomic Study on the Application of Magnetic Resonance Imaging with Gadoteric Acid in Addition to Contrast-Enhanced Computed Tomography in Diagnosis of Hepatocellular Carcinoma. 2021 , 102, 284-295	
550	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. 2021 , 30, 2455	1
549	3D Quantitative Ablation Margins for Prediction of Ablation Site Recurrence After Stereotactic Image-Guided Microwave Ablation of Colorectal Liver Metastases: A Multicenter Study. 2021 , 11, 757167	0
548	Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. 2021 , 25, 715-734	1
547	Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. 2021 , 17, 5013-5022	
546	Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. 2021 , 22,	0
545	Limited Prognostic Value of KRAS in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. 2021 , 1	1
544	RCC1 Expression as a Prognostic Marker in Colorectal Liver Oligometastases.. 2021 , 27, 1610077	0
543	A national dose analysis of guided tumor destruction: influence of sex, age, localization and destruction technique used.. 2022 , 12, 1968-1976	
542	Onkologika. 2021 , 579-638	
541	[Rapid Idyllaâmutational testing: Current and future theranostic applications].. 2022 ,	
540	Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.. 2022 , 1	
539	Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?. 2022 , 22, 17	0
538	LokoregionâRadionuklidtherapie. 2022 , 1-11	
537	Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.. 2022 ,	0
536	Curative resection of ureteral metastasis of rectal cancer: a case report and review of literature.. 2022 , 1	1

- 535 Treatment strategies for locally advanced rectal cancer with synchronous resectable liver metastasis. **2018**, 51, 1 1
- 534 Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy.. **2021**, 14, 17562848211066206 0
- 533 Cost-effectiveness analysis in radiology: methods, results and implications. **2021**, 194, 0
- 532 Yttrium-90 Internal Radiation Therapy as Part of the Multimodality Treatment of Metastatic Colorectal Carcinoma. **2021**, 1, 207-218
- 531 Emerging Therapeutic Agents for Colorectal Cancer.. **2021**, 26, 4
- 530 Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.. **2022**, 39, 1215
- 529 Impact of Body Composition on Prognosis and Dose-Limiting Toxicities on Metastatic Colorectal Cancer.. **2021**, 8, 671547 0
- 528 Is it worthwhile to perform closure of the pelvic peritoneum in laparoscopic extralevator abdominoperineal resection?. **2022**, 1
- 527 Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.. **2022**, 0
- 526 Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer.. **2022**, 14, 17588359211070643 0
- 525 Yttrium-90 transarterial radioembolization in patients with gastrointestinal malignancies.. **2022**, 24, 796 0
- 524 Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions.. **2022**, 1
- 523 Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective.. **2022**,
- 522 Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.. **2022**, 4
- 521 Multi-institutional analysis of outcomes for thermosphere microwave ablation treatment of colorectal liver metastases: the SMAC study.. **2022**, 1 0
- 520 [Re-visiting the Pronopall score ten years later: A multicenter retrospective study].. **2022**,
- 519 Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.. **2022**, 0
- 518 Complement System: An Immunotherapy Target in Colorectal Cancer.. **2022**, 13, 810993 0

517	Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the Histologic Growth Pattern.. 2022 , 14,	1
516	Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells.. 2022 , 2022, 3577928	0
515	A prognostic nomogram for intrahepatic progression-free survival in patients with colorectal liver metastases after ultrasound-guided percutaneous microwave ablation.. 2022 , 39, 144-154	0
514	Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.. 2022 ,	0
513	Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial.. 2022 , 12, 316	3
512	Local tumour control after radiofrequency or microwave ablation for colorectal liver metastases in relation to histopathological growth patterns.. 2022 ,	1
511	Left renal vein graft and in situ hepatic perfusion in hepatectomy for complete tumor invasion of hepatic veins: hemodynamic optimization and surgical technique.. 2022 , 1	0
510	Precision medicine for metastatic colorectal cancer in clinical practice.. 2022 , 14, 17588359211072703	2
509	Prognostic Impact of Total Lesion Glycolysis (TLG) from Preoperative F-FDG PET/CT in Stage II/III Colorectal Adenocarcinoma: Extending the Value of PET/CT for Resectable Disease.. 2022 , 14,	0
508	The new insight of treatment in Cholangiocarcinoma.. 2022 , 13, 450-464	2
507	Predictive biomarkers of drug response: Colorectal cancer as a model. 2022 , 199-240	0
506	Comparison of Colorectal Cancer Stem Cells and Oxaliplatin-Resistant Cells Unveils Functional Similarities.. 2022 , 11,	1
505	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥70 years.. 2022 , 163, 1-15	0
504	Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.. 2022 , 163, 163-176	3
503	The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.. 2022 , 31, 100531	0
502	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies.. 2022 ,	
501	Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion.. 2022 , 11,	2
500	A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial.. 2022 ,	

- 499 Aspirin synergizes with regorafenib to reduce growth of colorectal cancer.
- 498 Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management.. **2022**, 14, ○
- 497 Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study.. **2022**, 14, ○
- 496 Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.. **2022**, 7, 100391 1
- 495 Percutaneous electrochemotherapy in primary and secondary liver malignancies - local tumor control and impact on overall survival.. **2022**, 56, 102-110 3
- 494 Is precision medicine for colorectal liver metastases still a utopia? New perspectives by modern biomarkers, radiomics, and artificial intelligence.. **2022**, 28, 608-623 ○
- 493 Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer.. **2021**, 11, ○
- 492 Solitary colorectal liver metastasis: overview of treatment strategies and role of prognostic factors.. **2021**, ○
- 491 Gut microbiome and its role in colorectal cancer.. **2021**, 21, 1325 8
- 490 Treatment of metastatic colorectal cancer in the year 2020. **2021**, 14, 258-261
- 489 Lokoregionäre Radionuklidtherapie. **2022**, 1-11
- 488 Comparison of UGT1A1 polymorphism as guidance of irinotecan dose escalation in RAS wild type metastatic colorectal cancer patients treated with cetuximab or bevacizumab plus FOLFIRI as the first-line therapy.. **2022**, 1
- 487 Mucinous rectal cancers: clinical features and prognosis in a population-based cohort.. **2022**, 6, ○
- 486 Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial.. **2022**, 29, 10732748221080332
- 485 Nuclear medicine therapy of liver metastasis with radiolabelled spheres. **2022**, ○
- 484 Needle track seeding in colorectal carcinoma after local ablation by high-dose-rate brachytherapy: a retrospective study of 1,107 catheter placements.. **2022**, 14, 169-175
- 483 Liver Transplantation for Colorectal Cancer Liver Metastases. **2022**, 683-706
- 482 Chemotherapy in resectable or potentially resectable colon cancer with liver metastases.. **2022**, 1-10 ○

- 481 LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.. **2022**, o
- 480 IgG-like Bispecific Antibody CD3EpcAM Generated by Split Intein Against Colorectal Cancer.. **2022**, 13, 803059 o
- 479 -G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.. **2022**, 12, 826073 1
- 478 Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study.. **2022**, 14, o
- 477 [Oncological surgery in the interdisciplinary context-On the way to personalized medicine].. **2022**, 93, 234-241
- 476 Pure laparoscopic major liver resection after yttrium radioembolization: a case-matched series analysis of feasibility and outcomes.. **2022**, 1 1
- 475 Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. **2022**, 6,
- 474 Horseshoe hepatectomy : Another step pursuing the concept of parenchyma sparing major hepatectomies.. **2022**, 74, 783 1
- 473 Treatment pathways and associated costs of metastatic colorectal cancer in Greece.. **2022**, 20, 7 o
- 472 Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.. **2022**, 12, 813009
- 471 Perioperative second-line chemotherapy is beneficial for resectable liver metastases that occur during or early after adjuvant chemotherapy for colorectal cancer.. **2022**, 37, 805
- 470 Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis.. **2022**, 1
- 469 Effect of chemotherapy on tumour-vessel relationship in colorectal liver metastases.. **2022**, o
- 468 Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon Cancer.. **2022**, 29, 1370-1389 o
- 467 A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.. **2022**, 1 1
- 466 Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020.. **2022**, 14, 821-842 o
- 465 Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial).. **2022**, 14,
- 464 mFOLFOXIRI with or without bevacizumab for conversion therapy of mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial.. **2022**, 10, 171 o

- 463 Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases.. **2022**, 1
- 462 Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis.. **2022**, 14,
- 461 Impact of histological subtype on prognosis in stage IV colorectal cancer: A population-based cohort study.. **2022**, 17, e0264652 2
- 460 Genetic Characteristics Associated With Drug Resistance in Lung Cancer and Colorectal Cancer Using Whole Exome Sequencing of Cell-Free DNA.. **2022**, 12, 843561 0
- 459 Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer.. **2022**, 0
- 458 Does F-FDG PET/CT change the surgical management of potentially resectable colorectal liver metastases?. **2022**, 111, 14574969221083144
- 457 Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, microsatellite instability-high or mismatch repair-deficient colorectal cancer.. **2022**, 2
- 456 Management of chemotherapy dose intensity for metastatic colorectal cancer.. **2022**, 23, 141 0
- 455 Assessment Following ESMO Recommendations for Colorectal Liver Metastases. Is It Always Worth It?. **2022**, 10, 1
- 454 Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).. **2022**, 0
- 453 Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification.. **2022**, 12, 856575 0
- 452 Radioembolization, Principles and indications.. **2022**,
- 451 Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.. **2022**, 1
- 450 A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer.. **2022**, 12, 808808 1
- 449 Identification of CT Imaging Phenotypes of Colorectal Liver Metastases from Radiomics Signatures-Towards Assessment of Interlesional Tumor Heterogeneity.. **2022**, 14, 2
- 448 Hepatic resection for breast cancer related liver metastases: A single institution experience.. **2022**, 111, 14574969221088685
- 447 Software-based assessment of tumor margins after percutaneous thermal ablation of liver tumors: A systematic review.. **2022**, 0
- 446 Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. **2022**, 100427 0

445	The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases.. 2022 , 14,	2
444	Long-Term Comparative Study on the Local Tumour Control of Different Ablation Technologies in Primary and Secondary Liver Malignancies.. 2022 , 12,	1
443	Combined Estrogen Alpha and Beta Receptor Expression Has a Prognostic Significance for Colorectal Cancer Patients.. 2022 , 9, 739620	0
442	Basic cardiovascular risk assessment in naïve patients with colon cancer.. 2022 , 23, 318	
441	The Value of F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review.. 2022 , 12,	
440	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review.. 2022 ,	4
439	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.. 2022 , 14,	1
438	Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis.. 2021 , 101856	1
437	Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.. 2022 , 13, 795972	4
436	R1vasc surgery for colorectal liver metastases.. 2022 ,	1
435	Treatment intention and outcome in patients with simultaneously diagnosed liver and lung metastases from colorectal cancer.. 2022 ,	1
434	Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3-5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis.. 2022 , 1	5
433	Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study.. 2022 , 14,	1
432	Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis.. 2022 , 14,	0
431	Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer.. 2022 , 14, e23543	
430	Opportunities for personalizing colorectal cancer care: an analysis of SEER-medicare data.. 2022 ,	
429	Imaging of Oligometastatic Disease.. 2022 , 14,	0
428	Prognostic impact of inter-metastatic heterogeneity of viable tumour cells in colorectal liver metastases.. 2022 ,	

- 427 Clonality and timing of relapsing colorectal cancer metastasis revealed through whole-genome single-cell sequencing.
- 426 Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.. **2022**, 13, 841425 ○
- 425 Comparison of Mortality Rates in Patients Waiting for Liver Transplant and Patients With Colorectal Metastatic Tumors.. **2022**, 20, 273-278
- 424 BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications.. **2022**, 103647 ○
- 423 Exploration of Reduced Mitochondrial Content-Associated Gene Signature and Immunocyte Infiltration in Colon Adenocarcinoma by an Integrated Bioinformatic Analysis.. **2022**, 13, 832331 ○
- 422 Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry.. **2022**, 1-6 1
- 421 Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.. **2022**, 165, 116-124 2
- 420 Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer.. **2022**, 1 1
- 419 Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.. **2022**, 1 1
- 418 Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer. **2022**, 44, 1552-1563 ○
- 417 FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.. **2022**, 22, 359
- 416 Tumor-associated CD3- and CD8-positive immune cells in colorectal cancer: The additional prognostic value of CD8+ to-CD3+ ratio remains debatable.. **2022**, 44, 37-52 1
- 415 Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer.. **2022**, 173, 103646 ○
- 414 Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer.. **2022**, 173, 103657 ○
- 413 The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features.. **2022**, 106, 102382 2
- 412 Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.. **2022**, 166, 73-86 ○
- 411 Pattern of distant metastases and predictive nomograms in colorectal mucinous adenocarcinoma: a SEER analysis.. **2021**, 12, 2906-2918
- 410 Inoperable metastatic colorectal cancer with primary tumour : Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).. **2022**, 16, 40

409	Patients' Experiences of medicines on initiation of antineoplastic agents for the treatment of colorectal cancer: a qualitative study. 2021 , 11, e047749	0
408	Pathological Features and Prognostication in Colorectal Cancer.. 2021 , 28, 5356-5383	2
407	Development and Validation of a Targeted 'Liquid' NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer.. 2021 , 11,	0
406	Liver resection in elderly patients with extensive CRLM: Are we offering an adequate treatment? A propensity score matched analysis.. 2021 ,	
405	Assessment of Metastatic Colorectal Cancer Patients' Preferences for Biologic Treatments in Germany Using a Discrete Choice Experiment.. 2021 ,	
404	Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.. 2021 ,	0
403	FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial.. 2021 , 11, 766500	0
402	Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients.. 2021 , 13,	0
401	All You Need to Know About Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide. 2021 , OP2100624	5
400	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). 2021 ,	1
399	Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.. 2021 , 12, 778329	0
398	Comprehensive Imaging Characterization of Colorectal Liver Metastases.. 2021 , 11, 730854	1
397	Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.. 2022 ,	0
396	Ketogenesis attenuates KLF5-dependent production of CXCL12 to overcome the immunosuppressive tumor microenvironment in colorectal cancer.. 2022 ,	1
395	Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.. 2022 ,	3
394	High Dual Expression of the Biomarkers CD44v6/244 and CD44v6/PD-L1 Indicate Early Recurrence after Colorectal Hepatic Metastasectomy.. 2022 , 14,	0
393	Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio's prediction on effectiveness.. 2022 , 14, 920-934	0
392	First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.. 2022 ,	0

- 391 Zebrafish Patient-Derived Avatars from Digestive Cancers for Anti-cancer Therapy Screening.. **2022**, 2, e415 1
- 390 Management of single pulmonary metastases from colorectal cancer: State of the art.. **2022**, 14, 820-832 1
- 389 Percutaneous microwave ablation of disappearing colorectal liver metastases using US-MR fusion imaging guidance with integration of pre-chemotherapy imaging: a case report. **2022**, 100159
- 388 Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.. **2022**, 168, 34-40 0
- 387 Image_1.TIF. **2019**,
- 386 Image_2.TIF. **2019**,
- 385 Image_3.TIF. **2019**,
- 384 Image_4.TIF. **2019**,
- 383 Presentation_1.pdf. **2019**,
- 382 Table_1.DOCX. **2019**,
- 381 Table_2.DOCX. **2019**,
- 380 Table_1.docx. **2019**,
- 379 Table_2.xlsx. **2019**,
- 378 DataSheet_1.pdf. **2020**,
- 377 Data_Sheet_1.docx. **2019**,
- 376 Presentation_1.pdf. **2020**,
- 375 Table_1.docx. **2020**,
- 374 Data_Sheet_1.docx. **2020**,

373 Image_1.jpg. **2018,**

372 Image_2.jpg. **2018,**

371 Image_1.JPEG. **2018,**

370 Table_1.DOCX. **2018,**

369 Table_2.DOCX. **2018,**

368 Conversion therapy with the intent to perform radical local treatment may not be suitable for patients with 10 or more liver metastases from colorectal cancer.. **2022,** 0

367 Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure.. **2022,** 39, 620-626 0

366 Ablation for oligometastatic colorectal carcinoma in extrahepatic, extrapulmonary sites.. **2022,** 39, 633-638 1

365 Contemporary evidence on colorectal liver metastases ablation: toward a paradigm shift in locoregional treatment.. **2022,** 39, 649-663 1

364 Regionale Chemotherapie/Chemoembolisation von Lebermetastasen. **2022,** 1-12

363 Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis.. **2022,** 37, 1181-1188 0

362 Distant Metastasis Pattern and Prognostic Prediction Model of Colorectal Cancer Patients Based on Big Data Mining.. **2022,** 12, 878805 2

361 Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer; a post-hoc analysis of the randomized phase III-trial AGITG-MAX.. **2022,**

360 Early-Age-Onset Colorectal Cancer in Canada: Evidence, Issues and Calls to Action. **2022,** 29, 3149-3159

359 Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy. **2022,** 10, 1035 0

358 Development of novel models for predicting mismatch repair protein deficiency and relevant disease-free survival in colorectal cancer patients.. **2022,**

357 Thermal ablation in the management of oligometastatic colorectal cancer.. **2022,** 39, 627-632 1

356 The Evolving Treatment Landscape in -Mutated Metastatic Colorectal Cancer.. **2022,** 42, 1-10 1

- 355 Clinical management of metastatic colorectal cancer in the era of precision medicine.. **2022**, 8
- 354 Encorafenib in combination with cetuximab after systemic therapy in patients with BRAFV600E mutant metastatic colorectal cancer: German health technology assessment-driven analyses from the BEACON CRC study.. **2022**,
- 353 Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers. **2022**, 12,
- 352 External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort. **2022**, 14, 2356 0
- 351 Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy.. **2022**, 1
- 350 Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study.. **2022**, 22, 486 1
- 349 Development of an abdominal phantom for the validation of an oligometastatic disease diagnosis workflow.. **2022**, 0
- 348 Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.. **2022**, 20, 155 2
- 347 Clinical Significance of Early Carcinoembryonic Antigen Change in Patients With Nonmetastatic Colorectal Cancer. **2022**, 12, 0
- 346 Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.. **2022**, 168, 99-107 0
- 345 Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer.. **2022**, 13, 875764 0
- 344 A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach.. **2022**, 20, 9 1
- 343 Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. **2022**, 170, 64-72 0
- 342 Prognosis prediction of stage IV colorectal cancer patients by mRNA transcriptional profile.. **2022**, 0
- 341 A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases.. **2022**, 12, 1648-1659
- 340 Silencing circular RNA-friend leukemia virus integration 1 restrained malignancy of CC cells and oxaliplatin resistance by disturbing dyskeratosis congenita 1. **2022**, 17, 563-576 1
- 339 Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases.
- 338 Efficacy of risk-stratified indicators for adjuvant chemotherapy with fluorouracil and oxaliplatin after hepatectomy for colorectal cancer liver metastasis.

- 337 Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression. **2022**, 22,
- 336 A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma Model. **2022**, 23, 6059 1
- 335 Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study. 0
- 334 Outcomes of simultaneous resection for elderly patients with colorectal liver metastasis: A propensity score matching analysis.
- 333 Simple systemic index associated with oxaliplatin-induced liver damage can be a novel biomarker to predict prognosis after resection of colorectal liver metastasis. 1
- 332 A Novel Concept of a Phased-Array HIFU Transducer Optimized for MR-Guided Hepatic Ablation: Embodiment and First In-Vivo Studies. 12, 1
- 331 Novel acetylation-related gene signatures for predicting the prognosis of patients with colorectal cancer.
- 330 Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases. **2022**, 23, 6091 0
- 329 Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. 1
- 328 KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report. 12,
- 327 Prognostic value of disease-free interval in colorectal cancer: Is it time?. **2022**, 0
- 326 Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. **2022**, 17, e0269399
- 325 Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. 0
- 324 Nomogram Predicting the Survival of Young-Onset Patients with Colorectal Cancer Liver Metastases. **2022**, 12, 1395 0
- 323 Long-term outcomes following percutaneous microwave ablation for colorectal cancer liver metastases. **2022**, 39, 788-795 0
- 322 Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?.
- 321 Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?. 2
- 320 Hepatisch metastasiertes kolorektales Karzinom. **2022**, 13, 81-91

319 Development of a Fully Automated Method to Obtain Reproducible Lymphocyte Counts in Patients With Colorectal Cancer. Publish Ahead of Print,

318 Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. **2022**, 100342

317 Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis. **2022**, 7, 100511

316 Single-session transarterial chemoembolization combined with percutaneous thermal ablation in liver metastases 3 cm or larger. **2022**,

315 Local Therapies for Colorectal Cancer Oligometastases to the Lung. **2022**, 18, 45-53

314 Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.

313 Prediction of survival in patients with colorectal liver metastases- development and validation of a prognostic score model. **2022**,

312 Optimale Therapiesequenz beim synchron hepatisch metastasierten kolorektalen Karzinom.

311 Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.

310 Diagnostic accuracy of 6-slice spiral computed tomography for local staging of colon cancer: A systematic review and meta-analysis. **2022**, 10, 6483-6495

309 Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study. **2022**, 834, 146646

308 Clonality and timing of relapsing colorectal cancer metastasis revealed through whole-genome single-cell sequencing. **2022**, 543, 215767

307 Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer. **2022**, 15, 175628482211106

306 Literatur. **2022**, 151-163

305 Interventionelle Therapie bei endokrinen und neuroendokrinen Tumoren.

304 Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches. 12,

303 Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial. **2022**, 22,

302 Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. **2022**, 102433

- 301 Multifactorial Analysis of Clinical Prognosis of Liver Metastasis and Vascular Intervention Combined with Ablation in Colorectal Cancer. **2022**, 2022, 1-9
- 300 Clinical Characteristics of Metastatic Colorectal Cancer Combined with Gastrointestinal Perforation and Prognostic Value of Circulating Tumor DNA. **2022**, 2022, 1-5
- 299 Thermal Ablation for Colorectal Liver Metastases: The Time has Come.
- 298 Prognostic Models Incorporating RAS Mutation to Predict Survival in Patients with Colorectal Liver Metastases: A Narrative Review. **2022**, 14, 3223 0
- 297 CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. 12, 2
- 296 Analysis of reporting quality of clinical practice guidelines/consensuses on metastatic colorectal cancer based on the RIGHT checklist. **2022**,
- 295 Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer. 0
- 294 Development and validation of a prognostic scoring system for patients with colorectal cancer hepato-pulmonary metastasis: a retrospective study. **2022**, 22,
- 293 Assessment of a Size-Based Method for Enriching Circulating Tumour Cells in Colorectal Cancer. **2022**, 14, 3446 0
- 292 A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer. **2022**, 14, 3252
- 291 Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing. 12, 0
- 290 The Emerging Era of Personalised Medicine in Advanced Colorectal Cancer. 0
- 289 Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study. 1
- 288 Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset colorectal cancer: A retrospective cohort study on 34067 patients managed from 2000 to 2021 in a Chinese tertiary center. **2022**, 106780 1
- 287 Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study. **2022**, 22,
- 286 Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab. 12, 1
- 285 GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers. 00-00 0
- 284 Interventional oncology of liver tumors: how it all started and where are we now. 1

- 283 Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments. Volume 15, 747-756 0
- 282 Long-Term Outcomes of Perioperative Versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases: An International Multicentre Propensity-Score Matched Analysis with Stratification by Contemporary Risk-Scoring. 0
- 281 New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary. **2022**, 14, 3429 0
- 280 Longitudinal changes in personalized platelet count metrics are good indicators of initial 3-year outcome in colorectal cancer. **2022**, 10, 6825-6844 0
- 279 The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. **2022**, 18, 2733-2744
- 278 Adjuvant therapy following resection of colorectal liver metastases. **2023**, 247-257
- 277 Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
- 276 Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer. **2022**, 27, 2
- 275 Leberchirurgie 4.0 - OP-Planung, Volumetrie, Navigation und Virtuelle Realität.
- 274 Characterization of KRAS Mutational Regression in Oligometastatic Patients. 13, 2
- 273 A Label-Free Cell Sorting Approach to Highlight the Impact of Intratumoral Cellular Heterogeneity and Cancer Stem Cells on Response to Therapies. **2022**, 11, 2264 0
- 272 Impact of post-hepatectomy liver failure on morbidity and short- and long-term survival after major hepatectomy. **2022**, 6, 1
- 271 Radionuclide Therapy in Liver Tumors. **2022**, 231-257
- 270 Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer. **2022**, 22, 0
- 269 Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer. **2022**, 22,
- 268 Exosomal circPABPC1 promotes colorectal cancer liver metastases by regulating HMGA2 in the nucleus and BMP4/ADAM19 in the cytoplasm. **2022**, 8, 1
- 267 Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board. 1
- 266 Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer. 13, 0

- 265 Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. **2022**, 14, 3718 o
- 264 Combinatory anti-tumor activities of AQ4 and temsirolimus against colorectal cancer cells.
- 263 Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. o
- 262 Treatment Costs of Colorectal Cancer by Sex and Age: Population-Based Study on Health Insurance Data from Germany. **2022**, 14, 3836 1
- 261 Automated Computer-aided Detection of Lung Nodules in Metastatic Colorectal Cancer Patients for the Identification of Pulmonary Oligometastatic Disease. **2022**, o
- 260 Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. **2022**, 12, o
- 259 SIRT in 2025. o
- 258 WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-institutional Registry-based Study (BRACELET Study). **2022**,
- 257 Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients. **2022**, 14, 3952 1
- 256 DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview. o
- 255 The Screening and Consensus Based on Practices and Evidence (SCOPE) Program Results of a Survey on Daily Practice Patterns for Patients with Metastatic Colorectal CancerâA Swiss Perspective in the Context of an International Viewpoint. **2022**, 29, 5604-5615
- 254 Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer. 12,
- 253 The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany. **2022**, 14, 3825
- 252 Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases. **2022**, o
- 251 Does Elevated Pre-Treatment Plasma PD-L1 Level Indicate an Increased Tumor Burden and Worse Prognosis in Metastatic Colorectal Cancer?. **2022**, 11, 4815
- 250 Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer: Lessons Learned and Future Perspectives. **2022**, 23, 1320-1337 o
- 249 Patterns and Timing of Recurrence following CRS and HIPEC in Colorectal Cancer Peritoneal Metastasis. **2022**,
- 248 Role of interventional oncology for treatment of liver metastases: Evidence based best practice. 1

- 247 Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer. **2022**, 11, 4922
- 246 A Tumor-Organoid-based Precision Medicine Platform for the Prediction of Drug Sensitivity of Colorectal Cancer. 2200093
- 245 The value of diffusion kurtosis imaging and intravoxel incoherent motion quantitative parameters in predicting synchronous distant metastasis of rectal cancer. **2022**, 22,
- 244 Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): A model-based economic evaluation.
- 243 Astragalus mongholicus Bunge and Curcuma aromatica Salisb. inhibits liver metastasis of colon cancer by regulating EMT via the CXCL8/CXCR2 axis and PI3K/AKT/mTOR signaling pathway. **2022**, 17, o
- 242 Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
- 241 FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases âThe PARLIM trial (AIO KRK 0314). **2022**, 173, 297-306 o
- 240 Impact of baseline gadoxetic acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study. **2022**, 44, 101836 1
- 239 Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases. **2022**, 36, 91-98 o
- 238 First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer âFinal survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). **2022**, 173, 194-203
- 237 Effect of chemotherapy and tumor clearance in hepatic resections for colorectal liver metastases. A single-centre cohort study.. **2022**, 46, 100521
- 236 MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer. **2022**, 7, 100559 o
- 235 Systemic Treatments and Related Side Effects in Liver Tumors. **2022**, 259-270 o
- 234 The impact of COVID-19 pandemic in the diagnosis and management of colorectal cancer patients. **2022**, 15, 175628482211176 1
- 233 Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline. **2022**, 14, 175883592211117 o
- 232 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. o
- 231 Discovery of novel conjugates of quinoline and thiazolidinone urea as potential anti-colorectal cancer agent. **2022**, 37, 2334-2347 1
- 230 Implications of Liver-Directed Therapy for Postoperative Hepatic Metastasis from Esophageal Cancer. **2022**, 55, 397-404 o

229	Gustave Roussy Immune score for predicting postoperative complications and non-cancer death in elderly patients with colon cancer.	0
228	Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. 2022 , 8,	2
227	A comparison of the simultaneous, liver-first, and colorectal-first strategies for surgical treatment of synchronous colorectal liver metastases at two major liver-surgery institutions in Sweden. 2022 ,	1
226	Prognostic impact of conversion hepatectomy for initially unresectable colorectal liver metastasis.	0
225	Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT. 2022 ,	0
224	Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy. 14, 877-886	0
223	Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer.	2
222	SOULMATE: the Swedish study of liver transplantation for isolated colorectal cancer liver metastases not suitable for operation or ablation, compared to best established treatmentâ randomized controlled multicenter trial. 2022 , 23,	0
221	The Role of Biomarkers in the Management of Colorectal Liver Metastases. 2022 , 14, 4602	0
220	Imaging Standardization in Metastatic Colorectal Cancer: A Joint EORTC-ESOI-ESGAR Expert Consensus Recommendation. 2022 ,	1
219	Collaborative multi-feature extraction and scale-aware semantic information mining for medical image segmentation.	0
218	Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia. 2022 , 2022, 1-8	0
217	Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. OF1-OF10	0
216	CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice. 030089162211225	0
215	The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy. 13,	0
214	Prognostische und prädiktive Biomarker beim kolorektalen Karzinom. 2022 , 20, 184-190	0
213	Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis. 2022 , 14, 4340	0
212	Amaryllidaceae Alkaloids Decrease the Proliferation, Invasion, and Secretion of Clinically Relevant Cytokines by Cultured Human Colon Cancer Cells. 2022 , 12, 1267	0

211	Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. 2022 , 14, 1654-1664	0
210	Palliative primary tumor resection in minimally symptomatic patients with colorectal cancer and synchronous unresectable metastases: when is it necessary? (systematic review). 2022 , 21, 99-110	0
209	Ablation versus resection for resectable colorectal liver metastases - Health care related cost and survival analyses from a quasi-randomised study. 2022 ,	0
208	Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection. 2022 , 23, 11529	1
207	Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scoresâA retrospective, propensity score matching analysis. 12,	1
206	Clinical Response and Safety of Bevacizumab-awwb treatment in Patients with Metastatic Colorectal Cancer: A case series and review of the literature.	0
205	FDG metabolic parameter-based models for predicting recurrence after upfront surgery in synchronous colorectal cancer liver metastasis.	0
204	Current trends in regenerative liver surgery: Novel clinical strategies and experimental approaches. 9,	0
203	Curative-intent treatment of pulmonary metastases from colorectal cancer: A comparison between imaging-guided thermal ablation and surgery.	0
202	Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer. 1-11	0
201	Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).	0
200	Long-term outcomes of staged liver resection for synchronous liver metastases from colorectal cancer and the clinical impact of early recurrence: A single-center retrospective cohort study.	0
199	A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer. 2022 , 7, 100589	0
198	A population-based predictive model identifying optimal candidates for primary and metastasis resection in patients with colorectal cancer with liver metastatic. 12,	0
197	Changing patterns of multidisciplinary team treatment, early mortality, and survival in colorectal cancer. 2022 , 6,	0
196	Clinical outcomes of neoadjuvant chemotherapy for resectable colorectal liver metastasis with intermediate risk of postoperative recurrence: A multi-institutional retrospective study.	0
195	The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer. 2022 , 12, 1552	0
194	Panitumumab plus trifluridine/tipiracil as anti-Epidermal Growth Factor Receptor rechallenge therapy in chemo-refractory RAS wild-type metastatic colorectal cancer: the randomized phase 2 VELO trial.	0

- 193 Colorectal Cancer and the Obese Patient: A Call for Guidelines. **2022**, 14, 5255 O
- 192 Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). **2022**, O
- 191 Neoadjuvant Chemotherapy followed by Radiofrequency Ablation May Be a New Treatment Modality for Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study. **2022**, 14, 5320 O
- 190 Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy. 13, 1 I
- 189 Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation. **2022**, 21, 135-141 O
- 188 Emerging roles of mesenchymal stem cell-derived exosomes in gastrointestinal cancers. 10, O
- 187 Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. **2022**, 1 I
- 186 Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M). 1 I
- 185 Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab. O
- 184 External Validation of the Colon Life Nomogram for Predicting 12-Week Mortality in Dutch Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil in Daily Practice. **2022**, 14, 5094 O
- 183 A Workflow for Dosimetry of ⁹⁰Y Radioembolization Based on Quantitative ^{99m}Tc-MAA SPECT/CT Imaging and a 3D-Printed Phantom. **2022**, 12, 10541 O
- 182 Repeated hepatic resection for colorectal liver metastases: is this concept safe and feasible?. O
- 181 Safety, Feasibility and Technical Considerations from a Prospective, Observational Study of CIREL: Irinotecan-TACE for CRLM in 152 Patients. **2022**, 11, 6178 2
- 180 Analgesic efficacy and safety of nalbuphine versus morphine for perioperative tumor ablation: a randomized, controlled, multicenter trial. **2022**, 23, O
- 179 Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations. 1-6 1
- 178 Local ablation of hepatocellular carcinoma by interstitial brachytherapy: prediction of outcome by diffusion-weighted imaging. 028418512211297 O
- 177 Magnetic Resonance-Guided Focused Ultrasound in the Treatment of Colorectal Cancer Liver Metastases. O
- 176 Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma. O

175	Treatment of Metastatic Colorectal Cancer: ASCO Guideline.	4
174	Case report: Acute toxic myocardial damage caused by 5-fluorouracil—from enigma to success. 9,	0
173	Validation study of the JSHBPS nomogram for patients with colorectal liver metastases who underwent hepatic resection in the recent era - a nationwide survey in Japan.	0
172	Percutaneous ablation of liver metastases from colorectal cancer: a comparison between the outcomes of ultrasound-guided and CT-guided using propensity score matching.	0
171	Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. 2022 , 14, 4874	1
170	Effects of curcumin on 5-fluorouracil resistance of colon cancer cells through the PI3K/AKT/mTOR pathway via MACC1. 2022 , 102202	0
169	Disparities in treatment and survival for patients with isolated colorectal liver metastases. 2022 ,	0
168	Combinatory anti-tumor activities of 1,4-bis[2-(dimethylamino)ethylamino]-5,8-dihydroxyanthracene-9,10-dione (AQ4) and temsirolimus against colorectal cancer cells.	0
167	Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy.	0
166	MRI Volumetric Response after Yttrium-90 Radioembolization for Colorectal Liver Metastases: Predictability at Baseline and Correlation with Survival. 2022 ,	0
165	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up— 2022 ,	15
164	Eficácia e Segurança de Regorafenibe em Pacientes com Características de Bom Prognóstico no Tratamento do Câncer Colorretal Metastático: Análise de Subgrupo do Estudo CORRECT. 2022 , 68,	0
163	Evaluation of tissue shrinkage after CT-guided microwave ablation in patients with liver malignancies using Jacobian determinant. 2022 , 39, 1371-1378	0
162	Real-Life Experience of the Prognostic Significance of the Primary Tumor Location on the Timing of Colorectal Liver Metastases: A Retrospective Analysis. 2022 ,	0
161	Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer.	1
160	Advances in Delivery of Selective Internal Radiation Therapy (SIRT): Economic and Logistical Effects of Same-Stay Work-Up and Procedure in the Treatment of Unresectable Liver Tumors in England.	0
159	The impact of liver resection on survival for patients with metastatic breast cancer —A systematic review and meta-analysis. 2022 ,	0
158	New-Onset Tongue Weakness Due to Skull Base Metastases to Bilateral Hypoglossal Canals. 2022 , 1,	0

157	Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials. 2022 , 7, 100606	o
156	A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). 2022 , 177, 154-163	o
155	Active breathing control guided stereotactic body ablative radiotherapy for management of liver metastases from colorectal cancer. 2022 , 85, 469-475	o
154	Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer.	o
153	Physical and Quality of Life Changes in Elderly Patients after Laparoscopic Surgery for Colorectal CancerâA Prospective Cohort Study. 2022 , 19, 14711	1
152	Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC. 2022 , 14, 2468	o
151	Impacts of primary tumor location on outcomes in patients undergoing hepatectomy for colorectal liver metastasis vary according to tumor burden. 9,	o
150	EMT-Related Genes Have No Prognostic Relevance in Metastatic Colorectal Cancer as Opposed to Stage II/III: Analysis of the Randomised, Phase III Trial FIRE-3 (AIO KRK 0306; FIRE-3). 2022 , 14, 5596	o
149	CAR T-cells for colorectal cancer immunotherapy: Ready to go?. 13,	o
148	Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C study. 2022 ,	o
147	PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.	o
146	Prognostic differences between oligometastatic and polymetastatic disease after resection in patients with colorectal cancer and hepatic or lung metastases: Retrospective analysis of a large cohort at a single institution. 2022 ,	1
145	Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study. 2022 , 14, 5513	1
144	Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. 2022 , 7, 100603	o
143	Redefining Later-Line Therapy in Metastatic Colorectal Cancer. 31-37	o
142	Multidisciplinary Liver Tumour Board. 2022 , 511-520	o
141	Resection Margins. 2022 , 155-162	o
140	State-of-the-Art Integration of Multiple Kinase Inhibitors in the Treatment of Gastrointestinal Cancers. 38-46	o

- 139 A novel computational framework for integrating multidimensional data to enhance accuracy in predicting the prognosis of colorectal cancer. **2022**, 1, ○
- 138 Deep learning model based on contrast-enhanced ultrasound for predicting early recurrence after thermal ablation of colorectal cancer liver metastasis. ○
- 137 Biomarkers in the development of individualized treatment regimens for colorectal cancer. 9, 1
- 136 Gut microbiome in tumorigenesis and therapy of colorectal cancer. ○
- 135 Liver Venous Deprivation Versus Portal Vein Embolization Before Major Hepatectomy for Colorectal Liver Metastases: A Retrospective Comparison of Short- and Medium-Term Outcomes. ○
- 134 Greater expectations: meeting clinical needs through broad and rapid genomic testing. **2022**, ○
- 133 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Where do we stand?. ○
- 132 Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer. **2023**, 24, 46 ○
- 131 Adverse events associated with encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer: an in-depth analysis of the BEACON CRC study. **2022**, ○
- 130 Prognosis of unresectable stage IV Colon cancer with primary tumour resection. A multicenter study of minimally or asymptomatic primary tumour. **2022**, ○
- 129 Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study. **2022**, 14, 6075 ○
- 128 Association of HLA-G 3'UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer. **2022**, 14, 2737 ○
- 127 Survival Outcomes after Elective or Emergency Surgery for Synchronous Stage IV Colorectal Cancer. **2022**, 10, 3114 1
- 126 Analysis of Circulating Immune Subsets in Primary Colorectal Cancer. **2022**, 14, 6105 ○
- 125 Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. **2022**, 11, 7523 ○
- 124 Leberteilresektionen bei Lebermetastasen – neue translationale Konzepte. ○
- 123 Upfront Versus Delayed Thermal Ablation for Colorectal Liver Oligometastases: A Multicenter Retrospective Study Using Propensity-Score Matching. ○
- 122 Delphi initiative for early-onset colorectal cancer (DIRECT). International Management Guidelines. **2022**, ○

121	Predictive Factors for Local Recurrence after Intraoperative Microwave Ablation for Colorectal Liver Metastases. 2023 , 15, 122	0
120	The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis. 2022 , 15,	0
119	Inhibition of Vascular Endothelial Growth Factor Protects against the Development of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Wild-Type but Not in CD39-Null Mice. 2022 , 14, 5992	0
118	Trifluridineâtipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. 2022 ,	0
117	Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer. 2022 , 22,	0
116	Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.	0
115	Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. 2022 , 9, 1-92	0
114	Principe physique, indications et résultats des ablations tumorales percutanées en radiologie interventionnelle thoracique : radiofréquence, cryoablation et micro-ondes. 2022 ,	0
113	Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer. 2022 , 7, 100633	0
112	Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT). 2022 , 49,	0
111	A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. 2022 , 7, 100639	0
110	Detection of Circulating Tumor Cells Using the Attune NxT. 2023 , 24, 21	1
109	Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.	0
108	Radiofrequenz- und Mikrowellenablation. 2023 , 1-9	0
107	Current Targeted Therapy for Metastatic Colorectal Cancer. 2023 , 24, 1702	1
106	El oncólogo práctico: El sidedness. 2016 , 21,	0
105	DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?.	0
104	Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis. 2023 , 38,	0

- 103 Impact of neoadjuvant chemotherapy on post-hepatectomy regeneration for patients with colorectal cancer liver metastasis â Systematic review and meta-analysis. **2023**, 10
- 102 Multiomics Study of a Novel Naturally Derived Small Molecule, NSC772864, as a Potential Inhibitor of Proto-Oncogenes Regulating Cell Cycle Progression in Colorectal Cancer. **2023**, 12, 340 0
- 101 Efficacy of Neutrophil-to-Lymphocyte Ratio for Cancer-Specific Survival in Elderly Patients with Localized Colon Cancer: A Single Center Propensity Score-Matched Analysis. Volume 16, 1-9 0
- 100 Therapy with pembrolizumab in treatment-naïve patients with non-metastatic, mismatch repair deficient colorectal cancer. 0
- 99 TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients. 030089162211479 0
- 98 The Impact of Molecular Biology in the Seeding, Treatment Choices and Follow-Up of Colorectal Cancer Liver MetastasesâA Narrative Review. **2023**, 24, 1127 0
- 97 Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review. **2023**, 0
- 96 Contemporary Outcomes for the Curative Treatment of Colorectal Cancer Pulmonary Metastases. 0
- 95 Vascular reconstructions and transplant technologies in liver surgery (part I). **2023**, 46 0
- 94 A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions. 0
- 93 Percutaneous Electrochemotherapy (ECT) in Primary and Secondary Liver Malignancies: A Systematic Review. **2023**, 13, 209 1
- 92 Combining Selective Internal Radiation Therapy with Immunotherapy in Treating Hepatocellular Carcinoma and Hepatic Colorectal Metastases: A Systematic Review. 0
- 91 Use of Contrast Media During CT-guided Thermal Ablation of Colorectal Liver Metastasis for Procedure Planning is Associated with Improved Immediate Outcomes. 0
- 90 âProteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity predictionâ**2023**, 42, 1
- 89 Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study. **2023**, 8, 100748 0
- 88 Activation of cGAS-STING Pathway Is Associated with MSI-H Stage IV Colorectal Cancer. **2023**, 15, 221 0
- 87 The tumor microenvironment in gastrointestinal adenocarcinomas revealed a prognostic and immunotherapeutic biomarker. **2022**, 14, 10171-10216 0
- 86 Highly sensitive liquid biopsy Duplex sequencing complements tissue biopsy to enhance detection of clinically relevant genetic variants. 12, 0

- 85 Increasing Dosage of Leucovorin Results in Pharmacokinetic and Gene Expression Differences When Administered as Two-Hour Infusion or Bolus Injection to Patients with Colon Cancer. **2023**, 15, 258 ○
- 84 Perspective Chapter: Topoisomerase 1 and Colo Rectal Carcinoma. ○
- 83 Long-term stable disease with mFOLFOX6 chemotherapy plus cetuximab for bone marrow metastasis from rectal cancer: A case report. 13, ○
- 82 Less aggressive treatment for less aggressive disease? A retrospective single-center study of pulmonary-limited metastases associated with colorectal cancer. ○
- 81 A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases. ○
- 80 Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer PDXs. ○
- 79 Metabolism-Guided Optimization of Tryptophanol-Derived Isoindolinone p53 Activators. **2023**, 16, 146 ○
- 78 Management of Patients with Synchronous Liver Colorectal Cancer Metastasis. ○
- 77 New developments in targeted therapy for metastatic colorectal cancer. **2023**, 15, 175883592211485 ○
- 76 Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis. **2023**, 15, 175883592211461 ○
- 75 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy. **2023**, 23, ○
- 74 A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. **2023**, 22, 153303382311523 ○
- 73 Hepatectomy versus Chemotherapy for Resectable Colorectal Liver Metastases in Progression after Perioperative Chemotherapy: Expanding the Boundaries of the Curative Intent. **2023**, 15, 783 ○
- 72 Therapeutic landscape and future direction of metastatic colorectal cancer. ○
- 71 Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patients's survival. 10, ○
- 70 A CT-based radiomics approach to predict immediate response of radiofrequency ablation in colorectal cancer lung metastases. 13, ○
- 69 The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer. **2023**, 15, 805 ○
- 68 NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer. ○

- 67 The dilemma of the disappearing colorectal liver metastases: defining international trends in management. **2023**, ○
- 66 Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting. 13, ○
- 65 18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer. **2023**, 54, ○
- 64 Local interventions for colorectal cancer metastases to liver and lung. ○
- 63 Primary and Metastatic Lung Cancer: Rationale, Indications, and Outcomes of Thermal Ablation. **2023**, ○
- 62 The Management of Oligometastatic Disease in Colorectal Cancer: Present Strategies and Future Perspectives. **2023**, 103990 ○
- 61 European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer. **2023**, 115, 102541 ○
- 60 Pregnancy and neonatal outcomes among women with early-onset colorectal cancer: a nationwide caseâcontrol study. **2023**, 59, 101963 ○
- 59 Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance. **2023**, 182, 103920 ○
- 58 A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients. **2023**, 159, 114272 ○
- 57 Exploiting Liver CT scans in Colorectal Carcinoma genomics mutation classification. **2022**, ○
- 56 Brazilian Society of Surgical Oncology surgical standards for resectable colorectal cancer liver metastases. **2022**, 126, 28-36 ○
- 55 Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community. **2023**, 25, 1455-1462 ○
- 54 Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. 12, ○
- 53 H matologische Neoplasien und solide Tumore. **2022**, 85-151 ○
- 52 Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial). **2023**, ○
- 51 Posthepatectomy but not prehepatectomy chemotherapy was associated with a longer time to recurrence in patients with resectable colorectal liver metastases: Inverse probability of treatment weighting analysis. ○
- 50 Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases. 13, ○

- 49 Surgical management of liver metastasis from colorectal cancer. **2023**, 16, 31-35 o
- 48 Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer. **2023**, 13, o
- 47 Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients. o
- 46 Survival improvement for patients with metastatic colorectal cancer over twenty years. **2023**, 7, o
- 45 Targeting the "Undruggable" Driver Protein, KRAS, in Epithelial Cancers: Current Perspective. **2023**, 12, 631 2
- 44 Value and prognostic factors of repeat hepatectomy for recurrent colorectal liver metastasis. **2023**, o
- 43 Intentional R1 resection of liver metastases: A new treatment paradigm for patients with advanced colorectal cancer based on a propensity score-Matched case-control analysis. **2023**, 47, 102097 o
- 42 Drug-eluting beads loaded with irinotecan to treat synchronous liver-only metastases of colorectal cancer non-responsive to bevacizumab-based chemotherapy. o
- 41 New Advances in Molecular Typing of Gastric Cancer. **2023**, 13, 2392-2396 o
- 40 Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis. **2023**, 18, e0282017 o
- 39 CACA guidelines for holistic integrative management of rectal cancer. **2023**, 2, o
- 38 Combined Ablation and Resection for Colorectal Liver Metastases in the Minimally Invasive Surgical Era. **2023**, 33, 121-128 o
- 37 An update on locoregional percutaneous treatment technologies in colorectal cancer liver metastatic disease. 1-10 o
- 36 The Resection Rate of Synchronously Detected Liver and Lung Metastasis from Colorectal Cancer Is Low—A National Registry-Based Study. **2023**, 15, 1434 o
- 35 Evaluation of the safety and efficacy of ultrasound-guided percutaneous radiofrequency ablation for hepatocellular carcinoma and liver metastases adjacent to the gallbladder. **2023**, 40, o
- 34 Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIMISE study. o
- 33 Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. **2023**, 29, 605-614 o
- 32 Influence of Extrapertitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases. o

- 31 Case report and literature review: PET/CT in the evaluation of response to treatment of liver metastasis from colorectal cancer with DEBIRI-TACE. 13, ○
- 30 Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. ○
- 29 Liver transplantation in metastatic colorectal cancer: are we ready for it?. ○
- 28 Global survey on the surgical management of patients affected by colorectal cancer with synchronous liver metastases: impact of surgical specialty and geographic region. ○
- 27 Nursing care and management of adverse events for patients with BRAFV600E-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review. **2023**, 31, ○
- 26 Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report. ○
- 25 Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. **2023**, 15, 1679 ○
- 24 Does RAS Status Increase the Prevalence of Positive Resection Margin in Colorectal Liver Metastasis? A Systematic Review and Meta-Analysis. 000313482311567 ○
- 23 Locally recurrent rectal cancer and distant metastases: is there still a chance of cure?. **2023**, ○
- 22 Delaying Surgery After Neoadjuvant Chemotherapy Affects Survival in Patients with Colorectal Peritoneal Metastases: A BIG-RENAPE Network Multicentric Study. ○
- 21 Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study. ○
- 20 Histopathological Helsinki score of colorectal liver metastases predicts survival after liver resection. ○
- 19 The Impact of KRAS Status on the Required Surgical Margin Width for Colorectal Liver Metastasis Resection. **2023**, 12, 2313 ○
- 18 Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer. **2023**, 24, 5840 ○
- 17 The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) â a real- life data report 2013â2018. **2023**, 57, 103-110 ○
- 16 Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes -'A single centre experience from India. 13, ○
- 15 New frontiers in oncological imaging with Computed Tomography: from morphology to function. **2023**, ○
- 14 Kolonkarzinom: palliative Chirurgie. **2023**, 1-7 ○

- 13 Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. **2023**, 101477 ○
- 12 Impact of perineural invasion on the outcome of patients with synchronous colorectal liver metastases treated with neoadjuvant chemotherapy and surgery. ○
- 11 The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival. ○
- 10 Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer. ○
- 9 Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends. **2023**, 24, 7344 ○
- 8 Radiofrequency ablation of lung metastases of colorectal cancer: could early radiomics analysis of the ablation zone help detect local tumor progression?. ○
- 7 Efficacy of left colic artery preservation with D3 lymph node dissection in laparoscopic surgery for advanced sigmoid and rectal cancer. ○
- 6 2-4 weeks is the optimal time to operate on colorectal liver metastasis after neoadjuvant chemotherapy. **2023**, ○
- 5 Progress in companion diagnosis of colorectal cancer. **2023**, 2, 63-66 ○
- 4 The value of case reports in rare oncological scenarios: mixed method analysis of colorectal metastases from breast cancer. ○
- 3 Young-onset colorectal cancer. **2023**, 9, ○
- 2 Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer. ○
- 1 Comparison of the therapeutic efficacy between systemic chemotherapy with and without radiofrequency ablation for colorectal cancer liver metastases: A propensity score matching study. ○